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ABSTRACT 
 Surgery, radiation, and chemotherapy have been the primary options for cancer 
patients; however, the recent emergence of immunotherapy has revolutionized the cancer 
treatment paradigm.  Cancer immunotherapies employ a patient’s immune system to 
recognize and fight cancer, but recruiting immune cells to tumors specifically and in 
adequate numbers is a significant challenge.  Therefore, the goal of this thesis was to 
develop a technology that was capable of directing immune cell migration in an effort to 
promote antitumor immunity and combat cancer growth.  Specifically, we have packaged 
chemokines, signaling proteins that promote immune cell migration, inside temperature-
sensitive liposomes (TSLs).  These nanocarriers are capable of being thermally triggered 
to enable selective localized release of encapsulated chemokines at the tumor site and 
have shown previous success for delivery of conventional chemotherapies.  For the initial 
step in the design of the chemokine-loaded TSLs, multiple chemokines were investigated 
to select an optimal immune cell recruitment profile.  Furthermore, we have designed a 
novel liposomal composition to ensure sufficient stability and temperature-sensitive 
chemokine release.  The TSLs were shown to be capable of releasing chemokines to 
promote immune cell recruitment.  Additionally, the TSLs were shown in vitro to limit 
  vii 
cancer cell growth by increasing immune cell recruitment.  The administration of the 
chemokine in a mice tumor model demonstrated its ability to delay tumor growth and 
result in smaller tumors.  This strategy of encapsulating chemokines within TSLs paves 
the way for additional cancer immunotherapies and chemokine-based therapies.   
  
  viii 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGEMENTS ................................................................................................ v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES ............................................................................................................ xii 
LIST OF FIGURES ......................................................................................................... xiii 
LIST OF ABBREVIATIONS ........................................................................................... xv 
Chapter 1 Introduction  ....................................................................................................... 1 
1.1 Nanotechnology ........................................................................................................ 1 
1.1.1 Lipid-based Nanocarriers ................................................................................... 1 
1.2.1 Stimuli-Responsive Liposomes ......................................................................... 4 
1.2 Cancer Immunotherapy ............................................................................................. 7 
1.2.1 B cells as a therapeutic option ........................................................................... 9 
1.2.2 CXCL13 function............................................................................................. 13 
1.2.3 Chemokine-based therapies ............................................................................. 15 
1.3 Motivation and Scope ............................................................................................. 16 
1.3.1 Strategy and Aims ............................................................................................ 16 
Chapter 2 TSL Design process ......................................................................................... 18 
2.1 Scope ....................................................................................................................... 18 
2.2 Background ............................................................................................................. 18 
  ix 
2.2.1 Chemokine Function and Role in Tumor Immunity ........................................ 18 
2.2.2 The mechanisms of TSLs................................................................................. 19 
2.2.3 Liposome Formulation Process........................................................................ 21 
2.3 Material and Methods ............................................................................................. 23 
2.3.1 Transwell migration assay ............................................................................... 23 
2.3.2 Flow Cytometry ............................................................................................... 24 
2.3.3 Liposome Preparation ...................................................................................... 26 
2.3.4 TSL Characterization ....................................................................................... 26 
2.3.5 Statistical Analysis ........................................................................................... 27 
2.4 Results ..................................................................................................................... 27 
2.4.1 Chemokine Selection ....................................................................................... 27 
2.4.2 Chemokine-loaded TSL ................................................................................... 30 
2.5 Discussion ............................................................................................................... 31 
Chapter 3 ........................................................................................................................... 33 
3.1 Scope ....................................................................................................................... 33 
3.2 Background ............................................................................................................. 33 
3.2.1 Challenges of Liposome Therapies .................................................................. 33 
3.2.2 Challenges of TSL Therapies ........................................................................... 34 
3.3 Material and Methods ............................................................................................. 35 
3.3.1 CXCL13 Conjugation ...................................................................................... 35 
3.3.2 Liposome Composition .................................................................................... 36 
3.3.3 Liposome Release Studies ............................................................................... 36 
  x 
3.3.4 Statistical Analysis ........................................................................................... 37 
3.4 Results ..................................................................................................................... 38 
3.4.1 Evaluating Liposomes temperature-sensitivity ................................................ 38 
3.4.2 Liposomes stability in serum ........................................................................... 40 
3.4.3 TSL comparison in high serum ........................................................................ 42 
3.4.4 Optimized TSLs in cell culture serum ............................................................. 44 
3.4.5 Release kinetics of optimized TSLs ................................................................. 45 
3.4.6 CXCL13 release from optimized TSLS ........................................................... 47 
3.4.7 Long-term release of optimized TSLs ............................................................. 48 
3.5 Discussion ............................................................................................................... 50 
Chapter 4 TSL in vitro evaluation .................................................................................... 53 
4.1 Scope ....................................................................................................................... 53 
4.2 Background ............................................................................................................. 53 
4.3 Material and Methods ............................................................................................. 55 
4.3.1 Liposome Preparation ...................................................................................... 55 
4.3.2 Transwell migration and Co-culture assay ...................................................... 56 
4.3.3 Statistical Analysis ........................................................................................... 58 
4.4 Results ..................................................................................................................... 58 
4.4.1 CXCL13-loaded TSL induce migration........................................................... 58 
4.4.2 Cancer growth reduced by CXCL13-loaded TSLs .......................................... 61 
4.5 Discussion ............................................................................................................... 65 
Chapter 5 Evaluation of CXCL13 in vivo ......................................................................... 69 
  xi 
5.1 Scope ....................................................................................................................... 69 
5.2 Background ............................................................................................................. 69 
5.2.1 Challenges of Chemokine-based Therapies ..................................................... 69 
5.2.2 Role of intratumoral immune cells .................................................................. 71 
5.3 Material and Methods ............................................................................................. 72 
5.3.1 CXCL13 administration and serum detection.................................................. 72 
5.3.2 Mouse B16F10 tumor studies .......................................................................... 73 
5.3.3 Tumor digestion and TIL analysis ................................................................... 74 
5.3.4 Statistical Analysis ........................................................................................... 75 
5.4 Results ..................................................................................................................... 75 
5.4.1 CXCL13 plasma half-life study ....................................................................... 75 
5.4.2 CXCL13 delays tumor growth ......................................................................... 76 
5.4.3 Intratumoral immune cell analysis ................................................................... 80 
5.5 Discussion ............................................................................................................... 84 
Chapter 6 Conclusion ........................................................................................................ 90 
6.1 Summary ................................................................................................................. 90 
6.2 Future Directions .................................................................................................... 93 
6.2.1 Preclinical animal studies ................................................................................ 93 
6.2.2 Improving efficacy ........................................................................................... 94 
REFERENCES ................................................................................................................. 98 
CURRICULUM VITAE ................................................................................................. 110 
 
  xii 
LIST OF TABLES 
Table 1. CXCL13-loaded TSL Characteristics ................................................................. 31 
Table 2. TSL release summary ......................................................................................... 52 
 
 
 
  
  xiii 
LIST OF FIGURES 
2.1 The flow cytometry gating strategy for the migrated immune cells ........................... 25 
2.2 Immune cell migration induced by CXCL12, CCL19, and CXCL13 ........................ 28 
2.3 Flow cytometry analysis of migrated immune cells ................................................... 29 
2.4 Simplified schematic of TSLs loaded with CXCL13 ................................................. 30 
3.1 Release of 10 kDa FITC dextran from liposomes ...................................................... 39 
3.2 10 kDa FITC dextran liposomal release in varying serum content ............................ 41 
3.3 Release of 10 kDa FITC dextran from LTSL variants ............................................... 43 
3.4 Release of 10 kDa FITC dextran from NTSL and LTSL-10 in 10% serum ............... 45 
3.5 The release profile of 10 kDa FITC dextran from LTSL-10s over 30 minutes. ......... 46 
3.6 Release of Alexa Fluor 488-conjugated CXCL13 from LTSL-10s ............................ 48 
3.7 Long-term LTSL-10 release of 10 kDa FITC dextran and Alexa Fluor 488-conjugated 
CXCL13 ............................................................................................................................ 49 
4.1 The experimental set up for the co-incubation assay .................................................. 57 
4.2 Images of transmigrated immune cells. ...................................................................... 59 
4.3 Transwell migration of immune cells induced by CXCL13. ...................................... 60 
4.4 Growth of MC38-Tdt cells incubated directly with TSLs and CXCL13.................... 62 
4.5 10X microscopic images of co-incubated MC38-Tdt cells and immune cells ........... 63 
4.6 Growth inhibition of MC38-Tdt cells by transmigrated immune cells ....................... 64 
5.1 The serum levels of injected CXCL13 into mice over time ....................................... 76 
5.2 B16F10 tumor size was tracked over time between mice administered with saline or 
CXCL13 ............................................................................................................................ 78 
  xiv 
5.3 The endpoint tumor masses between mice administered with saline or CXCL13 after 
19 days .............................................................................................................................. 79 
5.4 The endpoint tumor masses were assessed between mice administered with saline or 
CXCL13 after 16 days ...................................................................................................... 80 
5.5 The flow cytometry panels depicting the gating strategy for TILs ............................. 81 
5.6 TIL profile between mice administered with saline or CXCL13 ............................... 83 
 
 
 
 
  
  xv 
LIST OF ABBREVIATIONS 
APC .................................................................................................. Antigen presenting cell 
BAFF................................................................................................. B cell activating factor 
BCR................................................................................................................ B cell receptor 
CAR ............................................................................................. Chimeric antigen receptor 
DMEM ........................................................................ Dulbecco's Modified Eagle Medium 
DLS ................................................................................................ Dynamic light scattering 
DOPE ............................................................................ Dioleoylphosphatidylethanolamine 
DPBS......................................................................... Dulbecco's Phosphate-buffered saline 
DPPC.................................................................................. Dipalmitoylphosphatidylcholine 
DSPE-PEG-2000...................................... Distearoylphosphatidylethanolamine–PEG-2000 
EPR ............................................................................. Enhanced permeability and retention 
FACS.............................................................................. Fluorescence activated cell sorting 
FBS ......................................................................................................... Fetal bovine serum 
FDC ................................................................................................ Follicular dendritic cells 
FITC ............................................................................................ Fluorescein isothiocyanate 
HBSS..................................................................................... Hank's Balanced Salt Solution 
HEPES ................................................ 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIFU ............................................................................... High intensity focused ultrasound 
HSPC................................................................ Hydrogenated soy L-α-phosphatidylcholine 
IFN-gamma .............................................................................................. Interferon-gamma 
IL-2 ................................................................................................................... Interleukin-2 
  xvi 
kDa ........................................................................................................................ kilodalton 
LTa1b2 .................................................................................................... Lymphotoxin a1b2 
LTSL ........................................................................... Low temperature-sensitive liposome 
LTSL-10 ............................................. Low temperature-sensitive liposome with 10% PEG 
MPPC ........................................................................... Monopalmitoylphosphatidylcholine 
NTSL............................................................................Non-temperature sensitive liposome 
PBS .............................................................................................. Phosphate-buffered saline 
PC .............................................................................................................Phosphorylcholine 
PCW ............................................................................................. Peritoneal cavity washout 
PD-1 .................................................................................. Programmed cell death protein 1 
PD-L2 ........................................................................................ Programmed death ligand 2 
PEG ........................................................................................................ Polyethylene glycol 
RES ............................................................................................ Reticuloendothelial system 
REV............................................................................................ Reverse-phase evaporation 
RPM ................................................................................................. Revolutions per minute 
RPMI medium ..................................................... Roswell Park Memorial Institute medium 
Tdt ......................................................................................................................... TdTomato 
TIL ...................................................................................... Tumor-Infiltrating Lymphocyte 
TNBC ...................................................................................... Triple negative breast cancer 
Treg cell .....................................................................................................Regulatory T cell 
TSL .................................................................................... Temperature-sensitive liposome 
 
1 
 
 
Chapter 1 Introduction  
1.1 Nanotechnology  
 Nanotechnology is the study and manipulation of matter at the “nano” (10-9) 
meter scale and has shown to be beneficial for a multitude of commercial, industrial, 
energy, and medical applications (Jeevanandam et al., 2018).  The eruption of the field 
has enabled scientist and engineers the ability to finely tune materials to create new 
structures and devices.  For instance, innovative materials such as carbon nanotubes are 
being developed with carefully designed electrical and mechanical properties for a 
variety of industrial applications (Donaldson et al., 2006).  Furthermore, a wide range of 
researchers have applied nanotechnology for the development of novel diagnostics and 
therapeutics (Wong et al., 2013).  The most notable application, drug delivery, has been 
greatly improved by utilizing nanomaterials and nanoparticles.  More specifically, 
nanoparticles can be utilized as drug carriers for existing cancer therapeutics to improve 
their selectivity, prolong circulation time, and reduce toxicity and adverse effects 
(McNeil et al., 2011).  As a whole nanotechnology offers many advantages for the 
advancement of cancer treatments and should be further employed for the development of 
future therapies.  
 
1.1.1 Lipid-based Nanocarriers  
 Liposomes are a specific type of lipid-based nanoparticle which resembles small 
cell vesicles and consist of at least one lipid bilayer.  These nanocarriers offer many 
advantages for drug delivery (Bozzuto et al., 2015).  For example, liposomes possess 
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large aqueous cores which allows sufficient entrapment of large biomolecules.  
Additionally, because they are composed of phospholipids which have a polar head group 
and nonpolar tail they have an overall amphipathic nature which allows encapsulation of 
both hydrophobic and hydrophilic molecules.  Hydrophilic molecules can be entrapped 
within the aqueous cores while hydrophobic compounds can be integrated into the lipid 
membrane.  Also, liposomes are biocompatible and associated with minimal toxicity 
(Sercombe et al., 2015).  Additionally, their overall physiochemical properties such as 
size and charge can be modulated as they can be composed of phospholipids with various 
characteristics (Akbarzadeh et al., 2013).  Liposomes which are 50-200 nanometers in 
size can passively target tumors by taking advantage of the enhanced permeability and 
retention (EPR) effect (Maeda et al., 2009).  Tumors are able to induce angiogenesis, the 
formation of new blood vessels; however, these new blood vessels are often chaotic and 
inefficient because they lack adequate smooth muscle layers and have wide fenestrations 
so they have greater permeability resulting in an EPR effect (Azzi et al., 2013).  Due to 
this, liposomes have been shown to leak into and preferentially accumulate into the tumor 
microenvironment (Fang et al., 2011).  
 Liposome research has significantly progressed in recent years in which many 
advances have been made to improve their capabilities.  Most notably, is the modification 
of their surface molecules to improve circulation time or facilitate targeted-delivery.  In 
greater detail, the addition of polyethylene glycol (PEG) chains to their surface helps 
them avoid recognition and clearance by reticuloendothelial system (RES), the main site 
for liposome accumulation, which in turn has shown to increase circulation time and 
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likelihood of tumor accumulation (Allen & Hansen, 1991; Li & Huang, 2009; Suk et al., 
2016).  Physically, the PEG chains help reduce charge-based contacts with proteins and 
small molecules.  Studies have shown that PEG-coated nanoparticles accumulate in the 
liver, a major component of the RES, one-third the amount as non-PEG coated 
nanoparticles (Jokerst et al., 2011).  In addition to PEG chains, liposomes can be 
conjugated with bioactive molecules such as small peptides, antibody fragments, and 
carbohydrates in order to target specific binding sites on cancer cells (Lukyanov et al., 
2004).  These conjugations are an improvement on passive targeting through the EPR 
effect, because they offer more specificity.  As such, previous studies utilizing xenograft 
tumor models, have demonstrated that packaging conventional chemotherapies into 
targeted nanoparticles improves tumor specificity (Gabizon et al., 2003a). 
 Liposomes have been proven to be useful for the delivery of cancer therapeutics.  
The most notable benefit of utilizing liposomes for cancer treatment is for delivering 
conventional chemotherapies in order to reduce off-target interactions and deleterious 
side effects.  This is exemplified by Doxil, a FDA-approved PEGylated liposomal 
formulation of Doxorubicin for the treatment of ovarian cancer and AIDS-related 
Kaposi's sarcoma (Andreopoulou et al., 2007; Simpson et al., 1993).  As with all 
conventional chemotherapies, Doxorubicin impacts both cancerous and healthy dividing 
cells.  Doxorubicin acts to prevent cell division by inhibiting topoisomerase II and has 
been used for a wide array of cancer types but is associated with significant 
cardiotoxicity.  Therefore, researchers encapsulated Doxorubicin within liposomes in 
order to decrease the frequency of interactions between Doxorubicin and healthy heart 
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cells.  Doxil has successfully shown to preferentially accumulate in tissue with increased 
permeability such as tumors (Barenholz 2012).  As a result of this increased tumor 
accumulation, less dosage is required which in turn helps to mitigate negative side 
effects.  Importantly, Doxil has been shown to be associated with minimal cardiotoxicity 
(Safra et al., 2000). The success of Doxil exemplifies the utility of employing liposome to 
improve cancer therapeutics.   
 
1.1.2 Stimuli-responsive Liposomes 
 Additionally, liposomes can be modified to alter their release capabilities and be 
responsive to an array of stimuli, such as changes in their surrounding pH or temperature 
(Bozzuto et al., 2015).  In greater detail, pH-sensitive liposomes have been designed to 
respond to the heavily acidic tumor microenvironments so when they accumulate at these 
sites they respond by releasing their contents (Chu & Szoka, 1994).  Otherwise, during 
circulation at physiological pH these liposomes remain relatively stable.  Additionally, 
when these pH-sensitives liposomes fuse or are enveloped by cells and reside in acidic 
endosomes they can disperse their contents inside the cells.  The mechanism by which the 
destabilization occurs for these liposomes is dependent upon the charges of the 
phospholipids used in the composition.  More specifically, pH-sensitive liposomes are 
commonly composed of the phospholipid, dioleoylphosphatidyl-ethanolamine (DOPE), 
which is cone-shaped and does not form bilayers but instead arranges in a hexagonal 
arrangement (Paliwal et al., 2015).  An amphiphilic molecule with a protonatable acidic 
group is included in the liposome composition and at physiological pH it helps stabilize 
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the cone-shaped phospholipids to form a bilayer (Lai et al., 1985).  At acidic pH, the 
amphiphilic molecule becomes protonated causing the bilayer to destabilize and allow the 
release of the interior contents (Torchilin et al., 1993).    
 In a similar manner, temperature-sensitive liposomes (TSLs) have been designed 
to release their encapsulated solute upon exposure to increased temperatures.  In greater 
detail, each phospholipid can be characterized by its phase transition temperature, the 
temperature at which the it transitions from a gel phase into a more liquid phase (Bozzuto 
et al., 2015).  This temperature is dependent upon the fatty acid chain length of the 
phospholipid.  The phospholipid, dipalmitoylphosphatidylcholine (DPPC), has two 16-
carbon fatty acid chain tails and a phase transition temperature of 41 °C.  As such, TSLs 
have been designed composed of DPPC so that at mild hyperthermic temperatures, 
between 39 °C and 42 °C, there is a significant shift in their bilayer permeability resulting 
in solute release (Needham et al., 2000).  Mild hyperthermic temperatures can be induced 
in vivo by utilizing high intensity focused ultrasound (HIFU) (Partanen et al., 2012).  
Currently, a similar process is used in patients to destroy renal tumors in which high 
energy radiofrequency waves is used to heat tumors (Wah et al., 2014).  Utilizing these 
tools, clinicians can induce localized heating at the tumor site to ensure selective release 
near the tumor.  An additional benefit of heating near the tumor site is that it promotes 
increased blood flow.  As a result, blood vessels near the tumor have greater permeation 
leading to an increased likelihood that administered TSLs accumulate in and release at 
the tumor site.   
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 Further development of TSLs has led to the generation of liposomes with 
increased temperature-sensitivity.  These low temperature-sensitive liposomes (LTSLs) 
are composed of DPPC, monopalmitoylphosphatidylcholine (MPPC), and 
distearoylphosphatidylethanolamine–PEG-2000 (DSPE-PEG-2000) (Needham et al., 
2001).  MPPC is similar in structure to DPPC except it is a lysolipid, having one of its 
fatty acid chain tails removed.  As a result, MPPC allow for more free space in the 
bilayer and helps to facilitate rapid increase in bilayer permeability upon exposure to 
mild hyperthermic temperatures.  The bulk of the LTSLs is composed of DPPC, with 
only a small percentage consisting of MPPC.  DSPE-PEG-2000 is a phospholipid 
conjugated with a PEG chain which acts to prolong circulation time.  Additionally, 
DSPE-PEG-2000 has also been shown to assist with MPPC’s ability to promote 
membrane permeability (Chen et al., 2013).   
 TSLs have been shown to be effective carriers for conventional chemotherapies.  
For instance, researchers have shown that Doxorubicin can be effectively encapsulated 
and released from TSLs upon heating (Gabizon & Martin, 1997; Tardi et al., 1996).  
Doxorubicin-loaded LTSLs, in combination with mild hyperthermia at the tumor site, 
demonstrated greater efficacy in inhibiting tumor growth than free Doxorubicin or 
Doxorubicin encapsulated in non-TSLs (Needham et al., 2001).  Currently, this therapy is 
being pursued in a number of cancer clinical trials (Lyon et al., 2017).  The benefits of 
liposomes and TSLs as drug carriers, highlight the opportunity for utilizing and 
innovating on LTSLs for the development of a novel cancer treatment. 
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1.2 Cancer Immunotherapy  
At the same time, cancer immunotherapy is a rapidly expanding field that is 
revolutionizing the cancer treatment paradigm.  Cancer immunotherapies are able to 
program and galvanize a patient’s immune system to combat cancer.  The current wave 
of cancer immunotherapies has been primarily aimed at empowering the T cell mediated 
antitumor immune response through modulating T cells to identify and attack cancer cells 
(Guinn et al., 2007).  T cells are able to recognize antigens on cancer cells and act 
directly to kill them or promote additional immunological responses.  This activity 
depends upon T cell receptors which initiate the recognition of tumor antigens and is 
regulated through multiple immune checkpoints, co-stimulatory or co-inhibitory signals, 
which researchers have targeted for modulation.  A common occurrence in tumor biology 
is the suppression of T cells by tumor cells via inhibitory signaling.  Researchers have 
developed immune checkpoint inhibitors to block tumor-derived immunosuppressive 
signaling in order to prevent T cells from being exhausted and ineffective against cancer 
(Darvin et al., 2018).  More specifically, by blockading the immune checkpoint 
programmed cell death protein 1 (PD-1) on T cells via the antibody Pembrolizumab, 
researchers have shown a survival benefit among patients with melanoma (Hamid et al., 
2019).  One limitation of this approach is that it is target-specific and requires expression 
of specific biomarkers or ligands within the tumor microenvironment to be effective.  
Additionally, tumor-associated macrophages have been demonstrated to remove immune 
checkpoint inhibitors on T cells, causing T cells to be further impacted by 
immunosuppressive signaling (Arlauckas et al., 2017).   
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Cell-based therapies such as adoptive cell transfer of re-engineered chimeric 
antigen receptor (CAR) T cells have demonstrated significant success, often curative, for 
the treatment of multiple leukemia types (Miliotou et al., 2018).  CAR T cells are 
generated by modifying T cells isolated from patients to recognize antigens associated 
with the patient’s cancer.  Although this therapeutic approach has shown great success for 
the treatment of hematologic cancers, it has not been as successful in clinical studies 
treating solid tumors (D’Aloia et al., 2018).  One challenge of this approach is recruiting 
a sufficient number of activated immune cells to the tumor site (Pockaj et al., 1994; 
Bernhard et al., 2008).  Solid tumors are not as accessible as hematologic cancers; 
therefore, CAR T cells have greater difficulty localizing to tumor sites which results in 
lower therapeutic success (Slaney et al., 2014).  The efficacy of cell-based cancer 
immunotherapies for the treatment of solid tumors is limited by the ability of activated 
immune cells to localize to the tumor site (Pockaj et al., 1994).   
The antitumor immune response depends on multiple facets which include 
immune cell tumor localization, immune cell tumor recognition, and immune cell 
activation.  As stated, a large focus within cancer immunotherapy has been on 
modulating immune cell activity, with immune checkpoint inhibitors, and immune cell 
tumor recognition, with CAR T cells.  However, there has been limited focus on 
improving immune cell tumor localization.  Each process is critical to ensuring that the 
immune system is capable of launching and maintaining an effective antitumor response. 
Sufficient immune cell tumor localization is important to ensure that immune cells are to 
interact and recognize tumor cells and upstart a cascade of additional activation and 
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response processes.  In general, higher levels of immune cells at the tumor site has been 
associated with improved survival for cancer patients (Gao et al., 2008).  Therefore, the 
work in this thesis focuses on developing a novel technology for improving immune cell 
tumor localization.   
 
1.2.1 B cells as a therapeutic option 
 Another important factor to consider in cancer immunotherapy is which immune 
cell types would be advantageous for improving antitumor immunity.  Although 
significant resources are being invested into modulating and understanding T cells in the 
context of the tumor immunity, the role of B cells should not be undervalued.  For 
instance, B cells have been shown to modulate T cell differentiation and activity as well 
as mediate T cell response to tumor antigens (Popi et al., 2016; Restifo et al., 2012).  
Also, B cells possess a diverse array of important immune functions ranging from 
antibody and cytokine production to phagocytosis of dying cells which may contribute to 
tumor immunity (Tsiantoulas et al., 2014; Vollmers et al., 2005).  Importantly, B cells are 
able to function as antigen presenting cells (APCs) by utilizing their B cell receptor 
(BCR) to recognize antigens and then process them for presentation (Rossetti et al., 
2018).  Additionally, a significant number of B cells are found in multiple tumor types so 
it is likely that they are an active participant in tumor immunity and should be further 
examined (Linnebacher 2013).  
 In greater detail, B cells possess multiple functions by which they can be 
beneficial for enhancing antitumor immunity either directly by interacting with tumor 
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cells or indirectly by assisting additional immune cells and functions in the tumor 
microenvironment.  For example, stimulated human B cells in vitro have demonstrated 
the ability to induce lysis of melanoma cells through the expression of TRAIL/Apo-2L 
(Kemp et al., 2004).  Additionally, in breast cancer tumor tissues, tumor-infiltrating 
lymphocytes (TIL) B cells have been reported to express granzyme B which acts to 
facilitate cell lysis of target cells.  Furthermore, these B cells in vitro demonstrated 
cytotoxic activity towards breast cancer cells (Hofman et al., 2012). This suggest that B 
cells may contribute to antitumor immunity by directly killing cancer cells in some 
capacity.   
 B cells also produce antibodies that bind to specific antigen epitopes and 
neutralize pathogens or label them for degradation and clearance by additional immune 
cells. This function is applicable to malignant cells as B cells are capable of generating 
antibodies directed towards intracellular and apoptotic tumor antigens (Brändlein et al., 
2003).  In mouse tumor models, TIL B cells antibodies reportedly bind to tumor cells and 
promote complement-dependent lysis, a process by which antibodies initiate a cascade of 
serum proteins to cause cytotoxicity (Shen et al., 2018).  Tumor-binding antibodies can 
promote tumor cell uptake by dendritic cells which can then drive cytotoxic T cells to 
attack the tumor (Tsou et al., 2016).  B cells can help facilitate the antitumor immune 
response though antigen presentation (Guo et al., 2009).  Studies have shown that B cells 
are important for presenting foreign and auto-antigens to helper T cells and activating an 
immune response (Hansen et al., 2001).  The depletion of B cells with anti-CD20 
monoclonal antibodies in a melanoma mouse model resulted in hampered helper and 
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cytotoxic T cell-mediated antitumor immune response (DiLillo et al., 2010).  
Additionally, activated B cells from cervical cancer patients have been shown to 
stimulate T cell-mediated antitumor immune responses (Rossetti et al., 2018).  These 
indirect mechanisms such as coating tumor cells with antibodies and presenting tumor 
antigens to T cells help contribute to a robust antitumor immune response. 
 Interestingly, the presence of TIL B cells has shown to be a positive prognostic 
marker for survival across multiple tumor types.  For example, analysis of colorectal 
cancer tissue samples demonstrated that high B cell infiltration was a good indicator for 
positive clinical outcome (Bindea et al., 2013).  Also, B cells have been shown to be good 
indicator for decreased risk of disease recurrence in colorectal cancer liver metastases 
(Meshcheryakova et al., 2014).  In a separate study, analysis of resected melanoma 
tumors treated with cancer vaccine therapy showed that those with significant B cell 
tumor infiltration were associated with 5-year disease free survival (Erdag et al., 2012).  
In multiple studies analyzing non-small-cell lung carcinoma (NSCLC) samples, high B 
cell tumor infiltration generally correlated with better clinical outcomes (Kinoshita et al., 
2016).  These studies suggest that improving B cell localization to the tumor may have a 
positive impact on survival. 
 Furthermore, B cells can be stratified into conventional B2 cells and innate-like 
B1 cells which have been identified in mice.  B1 cells have shown unique contributions 
to antitumor immunity and are characterized by their ability to self-renew and 
constitutively produce natural antibodies (Martin et al., 2001).  These antibodies have 
low affinity, are poly-reactive, and can recognize self-antigens.  One important function 
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of natural antibodies is recognizing phosphorylcholine (PC) which is a present in 
apoptotic cell membranes (Vas et al., 2012).  B1 cells also have the ability to phagocytose 
apoptotic cells (Gao et al., 2012).  This is important as dysregulation of proper apoptotic 
cell clearance can lead to necrosis and inflammation, both of which are associated with 
tumor progression (Hochreiter-Hufford et al., 2013; Elliot et al., 2010).  Therefore, B1 
cells may help contribute to maintaining homeostasis by identifying and clearing dying 
tumor cells.  Furthermore, B1 cells are able to stimulate T cell expansion via their high 
expression of CD80/CD86 and promote differentiation of helper T cells (Restifo et al., 
2012).  B1 cells have been shown to secrete the anti-inflammatory cytokine, IL-10, which 
can combat inflammation (Popi et al., 2004).  B1 cells are also capable of eliciting a 
response independent of T cells and are resistant to FAS-induced apoptosis (Rothstein et 
al., 2013). 
 A subpopulation of B1 cells, called L2pB1 cells, express programmed death 
ligand 2 (PD-L2) which can interact with PD-1 on T cells (Zhong et al., 2011).  Through 
this interaction, L2pB1 cells can differentially inhibit PD-1 high exhausted T cells to 
enrich for PD-1 low T cells which are more resistant to tumor PD-L2 immunosuppressive 
signaling (Mkrtichyan et al., 2012).  With this in mind, B1 and B cells in general, possess 
a plethora of mechanisms by which they can promote a more robust antitumor immune 
response and have been associated with improved survival among cancer patients.  
Therefore, focus should directed on employing B cells for a potential cancer 
immunotherapy. 
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1.2.2 CXCL13 Function 
 Given the significance of both B cells and immune cell tumor recruitment with 
respect to antitumor immunity, it is important to highlight the functions of the B cell 
chemokine, CXCL13, and its potential as a cancer immunotherapy.  Chemokines, a 
subclass of cytokines, are signaling proteins that act to drive cell migration.  CXCL13 has 
been implicated as a potential key modulator of antitumor immunity and is expressed by 
follicular dendritic cells (FDCs) and helper T cells (Wang et al., 2011).  It is a ligand for 
the CXCR5 chemokine receptor expressed primarily on B cells.  CXCL13 is known to be 
essential for naive B cell homing and organization within lymphoid follicles, sites critical 
for B cell-antigen interaction and B cell differentiation (Ansel et al., 2002).  Also, 
CXCL13 is required for naive B cells to express the cytokine, lymphotoxin a1b2 
(LTa1b2), which in turn promotes the development of FDCs.  This generates a positive 
feedback loop in which the FDCs can stimulate B cells and express CXCL13, leading to 
further B cell recruitment and LTa1b2 expression (Ansel et al., 2000).  This has been 
confirmed in vitro, in which the administration of CXCL13 to B cells led to the induction 
of LTa1b2 production.  There is also evidence that CXCL13 through CXCR5 signaling is 
able to enhance BCR-triggered B-cell activation by altering cytoskeleton dynamics (de 
Guinoa et al., 2011).  More specifically, the CXCL13-CXCR5 interaction triggers B cell 
polarization and reorganization of the actin cytoskeleton which results in membrane 
ruffling.  This in turn leads to a greater frequency of contact between the B cell 
membrane and target cell membrane.  The overall effect is that there is enhanced antigen 
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gathering at the B cell immune synapse.  Therefore, CXCL13 may not only be important 
for recruiting B cells, but also can potentially increase their activity.   
 In addition to its direct effects on B cells, CXCL13 may contribute to a greater 
antitumor immune response by improving immune cell tumor localization as there are 
multiple studies in which its elevated intratumoral levels have correlated with greater 
immune cell recruitment and prognosis.  Among colorectal cancer patients, increased 
intratumoral CXCL13 correlated with greater T cell and B cell tumor localization and 
prolonged patient survival (Bindea et al., 2013).  Administration of CXCL13 into the 
colonic submucosa of mice with colorectal cancer resulted in decreased tumor growth.  
Additionally, heightened intratumoral CXCL13 levels in HER2+ breast cancer patients 
correlated with better disease free survival (Razis et al., 2012).  Also, high expression of 
CXCL13 among triple negative breast cancer (TNBC) patients corresponded with better 
outcomes (Song et al., 2012).  Likewise, analysis of genome-wide cDNA expression of 
tumor samples from ovarian cancer patients revealed that high CXCL13 correlated with 
better prognosis (Rachidi et al., 2013).  These studies suggest that CXCL13 is able to 
hinder tumor progression by enhancing the number of immune cells at the tumor site, 
which is evidenced by its correlation with greater prognosis and survival in multiple 
tumor types.  Additionally, these studies provide support for the notion that immune cell 
tumor localization is important for ensuring a sufficient antitumor immune response and 
combating tumor growth.  With this in mind, delivering CXCL13 to the tumor may be 
beneficial for inhibiting tumor growth.  One strategy that is outlined in this thesis is to 
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employ TSLs for CXCL13 delivery which will allow clinicians to selectively trigger 
release at the tumor site using HIFU.   
 
1.2.3 Chemokine-based therapies 
 A multitude of chemokine-based therapies are being pursued as a cancer 
treatment; however, a major obstacle for these therapies is efficient delivery methods 
(Mohit et al., 2012).  Therefore, researchers have pursued loading these biomolecules into 
nanoparticles.  For instance, researchers have encapsulated the cytokine interferon-
gamma (IFN-gamma) into liposomes to serve as an adjuvant in a tumor cell vaccination 
procedure (Van Slooten et al., 2000).  IFN-gamma enables enhanced antigen 
presentation.  Liposomal delivery of IFN-gamma to tumor sites was shown to provide a 
persistent cytokine reservoir and demonstrated protective benefits towards injected 
cancer cells.  By packaging IFN-gamma inside liposomes, the researchers were also able 
to demonstrate an increase in the duration that the cytokine resided in the tumor site 
compared to free IFN-gamma.  Additionally, chemokines which attract neutrophils were 
encapsulated in polymer-based nanoparticles and shown to gradually release and promote 
influx of neutrophils at lymph nodes (Popova et al., 2015).  These limited studies uphold 
that nanoparticles can be employed for chemokine delivery, but ultimately more work is 
necessary in this area of research and doing so would potentially benefit multiple 
therapeutic avenues.  The work in this thesis makes advances in chemokine delivery as 
we outline the process by which we design and employ TSLs for CXCL13 delivery.   
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1.3 Motivation and Scope 
The motivation of this thesis was to design chemokine-loaded TSLs and employ them to 
establish a potential cancer immunotherapy strategy.  By combining two growing areas of 
research, nanotechnology and cancer immunology, this thesis exemplifies an innovative 
interdisciplinary approach towards developing cancer therapies.  The scope of this thesis 
was to outline the design principles of these nanoparticles and evaluate their effectiveness 
initially through a series of in vitro experiments.  In vivo experiments were then 
performed to lay the foundation for the implementation of these nanoparticles as a 
potential cancer treatment.  
 
 1.3.1 Strategy and Aims  
We have designed TSLs encapsulated with chemokines in order to direct immune cell 
migration.  The long-term objective of these chemokine-loaded TSLs is to improve 
immune cell tumor localization and be adapted as part of an innovative cancer 
immunotherapy strategy.  Upon thermal triggering, TSLs that have accumulated within 
the tumor space will release entrapped chemokines to establish a local gradient and 
recruit immune cells to the tumor site leading to an enhanced antitumor immune 
response.  We hypothesize that chemokine-loaded liposomes can be leveraged as an 
innovative cancer immunotherapy strategy.  In this thesis, the design process of the 
chemokine-loaded TSLs is outlined in Chapter 2.  In Chapter 3, the chemokine-loaded 
TSLs were optimized for in vivo-like conditions and its release capabilities were 
evaluated.  In Chapter 4, the efficacy of the chemokine-loaded TSLs in recruiting 
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immune cell and ability to impact cancer cell growth was assessed.  In Chapter 5, 
preliminary in vivo experiments were executed to set the groundwork for implementing 
the chemokine-loaded TSLs as a potential cancer therapy.  In Chapter 6, we postulate on 
the steps necessary to adapt and improve the efficacy of the chemokine-loaded as a 
cancer immunotherapy.  
The aims of the thesis are as follows: 
Aim 1: Design TSLs capable of rapid release of chemokine upon mild hyperthermic 
temperatures and sustained release at physiological temperature.  (Chapter 2-3) 
Aim 2: Evaluate ability of chemokine-loaded TSLs to recruit immune cells and reduce 
cancer growth.  (Chapter 4) 
Aim 3: Determine the impact of free CXCL13 on tumor growth and immune cell tumor 
localization, and characterize its half-life.  (Chapter 5) 
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Chapter 2 TSL design process 
2.1 Scope 
 This chapter details the design process involved for developing chemokine-loaded 
TSLs for a potential cancer immunotherapy.  Background will be provided on various 
chemokines and their impact on immune cell recruitment and tumor immunity.  
Additional information will be presented on TSLs and the mechanisms by which they are 
able to respond to temperature changes.  This chapter will also focus on multiple 
liposome formulation processes and the challenges associated with chemokine 
encapsulation.  An experimental investigation was executed to determine the optimal 
chemokine for attracting B cells, and CXCL13 proved to be most effective.  Additional 
studies were performed to determine a proper loading procedure for chemokines into 
TSLs.  The results demonstrated that reverse-phase evaporation (REV) can be employed 
to encapsulate chemokines within TSLs, which provided the framework for subsequent 
experiments with the TSLs in the additional chapters.   
 
2.2 Background 
2.2.1 Chemokine Function and Role in Tumor Immunity 
 Chemokine selection is a vital decision for designing chemokine-loaded TSLs that 
can contribute to bolstering the antitumor immune response.  Chemokines are 
preferentially, not exclusively, selective for specific immune cell types.  While CXCL13 
has been shown to be effective for B cell recruitment, and more specifically B1 cell 
trafficking to lymph nodes, it is not the only chemokine that attracts B cells.  For 
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instance, both chemokines CXCL12 and CCL19 are able to recruit B cells and are known 
to attract additional lymphocytes.  Additionally, these chemokines are vital for ensuring 
proper immunological homeostasis and have shown potential benefits for enhancing the 
antitumor immune response.  In more detail, CXCL12 binds to CXCR4 and is important 
for angiogenesis by recruiting endothelial progenitor cells.  It helps to retain 
hematopoietic stem cells in the bone marrow and is essential for proper embryogenesis 
(Janssens et al., 2017).  In metastatic breast cancer animal models, CXCL12 has been 
shown to induce cancer-targeted CD8+ T cell cytotoxicity (Williams et al., 2010).  
Additionally, CCL19 interacts with CCR7 to recruit B cells, dendritic cells, and T cells 
and is essential for T cell trafficking in the thymus (Stein et al., 2005).  Also, in a lung 
cancer animal model, CCL19 was shown to promote an IFN-gamma driven antitumor 
immune response (Hillinger et al., 2003).  Furthermore, there is significant crosstalk 
between chemokine receptors as CXCR5, CCR7, and CXCR4 work together to promote 
B cell recruitment to Peyer’s patches (Okada et al., 2002).  Given that chemokines can act 
in tandem and on multiple immune cell types, multiple chemokines were evaluated for 
encapsulation into chemokine-loaded TSLs.  More specifically, based on the beneficial 
impacts of CXCL13, CXCL12, and CCL19 on antitumor immunity, their ability to recruit 
B cells generally and B1 cells specifically was assessed.    
 
2.2.2 The mechanisms of TSLs 
 TSLs have been designed such that upon exposure to mild hyperthermic 
temperatures, 39 °C – 42 °C, there is an increase in their membrane permeability allowing 
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the outward diffusion of their encapsulated contents.  Each phospholipid has a phase 
transition temperature at which it shifts from solid-barrier arrangement to a more fluid-
like arrangement.  For instance, the phospholipid HSPC has a phase transition 
temperature of 53 °C and is used in non-TSL formulations, whereas DPPC, which has a 
phase transition temperature of 41 °C, is typically used in TSLs formulations.  Although 
non-TSLs composed of HSPC are sensitive to 53 °C, the term “temperature-sensitive” 
refers to liposomes that are responsive to the mild hyperthermic temperature range, 39 °C 
– 42 °C.  This temperature range can be safely induced in vivo via high intensity focused 
ultrasound without causing significant damage to the surrounding areas.  
 Various fatty acids can be added to the liposome formulation in order to enhance 
permeabilization of the lipid bilayer upon heating.  For instance, studies have shown that 
the addition of MPPC to traditional TSLs lowers the threshold temperature for 
permeabilization and promotes rapid release of liposomal contents (Anyarambhatla & 
Needham, 1999).  MPPC has the same phase transition temperature as DPPC and is a 
lysolipid, having one fatty acid tail removed.  Upon exposure to mild hyperthermic 
temperatures, the bilayer permeability increases and MPPC allows for more room for 
encapsulated solutes to escape.  The use of MPPC in LTSLs has successfully proven to 
facilitate rapid release of small chemotherapeutic agents (<500 Daltons) such as 
Doxorubicin (Needham et al., 2001).  Cholesterol is another modulating agent which acts 
as a buffer during the phase transition process, mitigating changes in the bilayer 
permeability but still allowing for solute release (Kaddah et al., 2018).  These 
components are important to consider when designing chemokine-loaded TSLs.  
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Ultimately, due to the proven success of LTSL, this was the initial liposome composition 
chosen for the design of the chemokine-loaded TSLs.   
 
2.2.3 Liposome Formulation Process 
 Loading of large biomolecules such as chemokines into liposomes is challenging.  
The bulk of liposomes have been developed for the delivery of small molecules, less than 
1000 Daltons (Zylberberg et al., 2006).  Furthermore, the standard liposome preparation 
method of thin-film hydration and extrusion has not been demonstrated to generate 
liposomes with sufficient encapsulation of large biomolecules such as chemokines which 
have a size of about 10 kilodaltons (kDa) (Bozzuto et al., 2015).  During this process 
lipids are mixed together in an organic nonpolar solvent and dried to generate a thin lipid 
film.  The addition of an aqueous medium such as water or PBS disperses sheets of the 
film, which self-assemble into polydisperse vesicles.  Theses liposomes can be quite large 
and non-uniform requiring further processing.  The liposomes can be filtered through a 
mini-extruder with various membrane pore sizes to adjust their final diameter.  This 
extrusion process yields uniform particles, but can cause a loss of material and rupture of 
the liposomes resulting in loss of encapsulated solute.  Due to the high molecular weight 
of chemokines, a low encapsulation efficiency would be expected in the initial hydration 
process and potentially decrease further due to the extrusion procedure.  
 Fortunately, there are additional methods for liposome preparation such as the 
freeze-drying method.  In this process, lipids and water-soluble materials are dissolved in 
tert-butyl alcohol to form a monophase solution, which is then freeze-dried and 
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rehydrated (Li et al. 2004).  This process can be repeated and can also be performed with 
a double emulsion consisting of two polar phases and one nonpolar phase containing 
lipids.  This method is beneficial for ensuring that the prepared liposomes are sterile and 
have a uniform distribution, two characteristics important for scaling up production for a 
pharmaceutical application.  However, one limitation of this method is that the 
encapsulation efficiency can vary significantly depending on the physiochemical 
properties of the molecule to be encapsulated.   This loading procedure may not be ideal 
for proteins such as chemokines, which can be damaged by multiple freeze-thaw cycles.   
 Previously, the reverse-phase evaporation (REV) method has proven to be an 
effective preparation process for efficient loading of small or large biomolecules into 
liposomes (Szoka & Paphadjopoulos, 1978).  This technique takes advantage of the 
amphipathic nature of phospholipids to reorient them into a lipid bilayer structure (Ko et 
al., 2012).  During this process, the interior lipid leaflet is arranged in the structure of a 
reverse micelle which is orientated with all the phospholipid heads pointing inward and 
tails point outward.  In this step, the bulk of the solution is nonpolar and a small amount 
is polar causing the phospholipids to self-arrange so that their nonpolar tails minimize the 
number of interactions with the polar molecules.  Methanol is added to ensure that the 
nonpolar and polar solvent are miscible and able to mix together.  As a result, the 
phospholipids form a reverse micelle with the hydrophilic solute, in this case, chemokine, 
entrapped in the aqueous core.  The addition of more nonpolar and polar solvents enables 
a solution separation and allows for the removal of the added methanol.  Additional 
phospholipids, in nonpolar solvent, and a small amount of polar solvent are added to 
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make up the outer lipid leaflet.  The excess phospholipids are freely floating in the 
predominately nonpolar solution.  A rotary evaporator is used to specifically remove the 
nonpolar solvent in the solution.  During this evaporation process, as the amount of 
nonpolar solvent decreases, the excess phospholipids orient their nonpolar tails to 
minimize polar interactions with the surrounding polar molecules.  As a result, these 
phospholipids collapse around the established reverse micelles leading to the formation 
of a lipid bilayer.  A major advantage of REV is that during the initial reverse micelle 
formation, a large volume is entrapped which allows for high encapsulation efficiency of 
large biomolecules such as chemokines.  Additionally, the final liposomes are relatively 
uniform and do not require further extrusion.  Therefore, REV was used to attempt to 
encapsulate chemokines inside TSLs.  
 
2.3 Material and Methods 
2.3.1 Transwell migration assay 
Mouse immune cells, peritoneal cavity washout (PCW) cells, were collected by injecting 
10 milliliters (ml) of Hank's Balanced Salt Solution (HBSS) with 2% fetal bovine serum 
(FBS) into the peritoneal cavity of mice as previously reported (Ray et al., 2010).  The 
PCW cell population is composed of 50-60% B cells, 5-10% T cells, and about 30% 
macrophages. Also, the PCW population serves as a major reservoir of B1 cells with two-
thirds of the B cells being B1 cells.  Transwell migration assays with PCW cells in 10% 
serum-containing media were performed as previously described (Moratz et al., 2004).  
5-μm Corning Costar transwell chambers were used for this assay (Cambridge, MA).  
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Mouse CXCL13, CXCL12, and CCL19 were purchased from Biolegend (San Diego, 
CA).  The chemokine concentration evaluated for CXCL13, CXCL12, and CCL19 was 
0.3 ug/ml for each transwell.  Each condition was evaluated in triplicates.  The incubation 
period for the assay was 6 hours as this was the optimal duration for recording immune 
cell migration.  The number of recruited immune cells per well was counted using the 
Nexcelom Celigo microwell plate imager (Lawrence, MA). 
 
2.3.2 Flow Cytometry 
Immune cells that migrated to the bottom chamber of the transwell were stained for 
further characterization.  Three wells per condition were pooled together to ensure 
sufficient number of cells for staining.  The cells were stained as previously described 
(Lee et al., 2015).  B220 PerCp-Cy5.5, CD-19 BUV395, and PD-L2 BV421 antibodies 
were purchased from BD Biosciences (San Jose, CA).  CD5 PE-Cy7, IgM APC, and 
CD11b APC-Cy7 antibodies were purchased from Biolegend (San Diego, CA). The 
Live/Dead AmCyan stain was procured from Thermo Fisher Scientific (Waltham, MA).  
Flow cytometry was performed with the cells within 24 hours of staining using the BD 
LSRII and analyzed with FlowJo.  The gating strategy for the flow cytometry analysis of 
the migrated cells is demonstrated in Figure 2.1.    
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Figure 2.1 The flow cytometry gating strategy for the migrated immune cells.  PCW cells 
were stained and analyzed to establish a gating strategy.  Total lymphocytes in the PCW 
cell population were selected and then separated into live and dead cells.  Of the live 
cells, they were further stratified as being T cells, B1 cells and B2 cells.  
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2.3.3 Liposome Preparation 
The TSLs were composed of 1, 2-dipalimitoyl-sn-glycero-3-phosphocholine (DPPC), 1-
palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (MPPC), and 1,2-distearoyl-sn-
glycero-3-phosphatidylethanolamine-n–[methoxy(polyethylene glycol)-2000] (DSPE-
PEG-2000) from Avanti Polar Lipids (Alabaster, AL).  The liposome formulation was 
based on the previously established LTSL formulation (Needham et al., 2001).  A 40:1 
lipid-to-chemokine mass ratio was used for the liposome formulation.  CXCL13 was 
encapsulated inside the TSLs using REV.  Modifications were made to a previously 
established REV procedure (Ko et al., 2012).  More specifically, adjustments were made 
to the starting solutions to ensure reproducibility across liposome batches.  The volume 
ratio of the initial nonpolar solvent-to-polar solvent was kept at 4:1.  Also, DSPE-PEG-
2000 was added only with the outer excess lipids.  Non-encapsulated CXCL13 was 
separated from the TSLs by extensive dialysis for 48 hours in 4 liters of PBS with a 300 
kDa membrane pore-sized dialysis tubing from Spectrum Labs (Billerica, MA).  Dialysis 
was performed at 4 °C to minimize liposome leakage and the PBS was changed once after 
24 hours. 
 
2.3.4 TSL Characterization 
Encapsulation of CXCL13 inside the TSLs was determined using the CBQCA Protein 
Quantitation Kit purchased from Thermo Fisher Scientific (Waltham, MA).  This protein 
kit detects any primary amines in the measured sample.  The only primary amines in the 
liposome solution belonged to CXCL13.  The liposomes were incubated at 50 °C for 30 
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minutes prior to using the protein kit to ensure that CXCL13 was accessible.  The 
CXCL13 used for generating a standard curve was also heated.  Additionally, empty 
liposomes, liposomes prepared without CXCL13 were used as a negative control.  
Samples were incubated for 1 hour before reading with the Molecular Devices 
SpectraMax M5 Microplate Reader with excitation and emission wavelengths of 465 nm 
and 550 nm, respectively (Downingtown, PA).  Linear regression of the standard curve 
was used to determine the amount of encapsulated CXCL13 within the liposome sample. 
The encapsulation efficiency was determined by comparing this value to the initial 
amount of CXCL13 used in the formulation.  Liposome sizing and zeta potential was 
determined by dynamic light scattering (DLS) using the Brookhaven 90plus Nano-
Particle Sizer with Zeta Potential from Brookhaven Instruments (Holtsville, New York).  
 
2.3.5 Statistical Analysis 
For the transwell migration assay the data are presented as mean ± standard deviation of 
experiments in triplicates. The data were analyzed with Welch’s t-test (p-value ≤ 0.05).   
 
2.4 Results 
2.4.1 Chemokine Selection 
 The first set of experiments was to evaluate the ability of various chemokines to 
recruit immune cells, with an interest in B cells and B1 cells, specifically.  Transwell 
migration assays were performed with CXCL12, CCL19, and CXCL13.  As shown in 
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Figure 2.2, the total number of recruited immune cells was essentially the same for all the 
chemokines.   
 
 
Figure 2.2.  Immune cell migration induced by CXCL12, CCL19, and CXCL13.  
Transwell migration assays were performed using 0.3 ug/ml of the following CXCL12, 
CCL19, and CXCL13.  All the chemokines induced significantly more immune cell 
migration compared to media.  However, there was no significant differences in the total 
number of migrated immune cells across all three chemokines.  (*p <0.05). 
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Figure 2.3.  Flow cytometry analysis of migrated immune cells.  Transmigrated immune 
cells were stained with various surface markers and analyzed using flow cytometry.  The 
presented migrated cells are a percentage of total living cells per condition.   
 
 The PCW population is a collection of B cells and T cells, as well as additional 
immune cells; so although in general each chemokine recruited the same number of 
immune cells, there were differences with respect to which immune cell types were 
recruited (Ray et al., 2010).  As shown in Figure 2.3, each chemokine induced a different 
profile of recruited immune cells.  For example, CXCL13 had the greatest enrichment of 
B1 cells compared to CXCL12 and CCL19.  In contrast, CXCL12 and CCL19 had 
greater recruitment of T cells compared to CXCL13 which was consistent with previous 
studies (Ottoson et al., 2001; Nandagopal et al., 2011).  Additionally, all the chemokines 
promoted greater recruitment of B2 cells compared to the negative media control.  The 
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goal of this experiment was to determine which chemokine was most effective in 
recruiting B cells and B1 cells.  Therefore, based on these results CXCL13 was selected 
for the design of the chemokine-loaded TSLs as demonstrated in Figure 2.4.  
 
Figure 2.4. Simplified schematic of TSLs loaded with CXCL13. The lipid bilayer is 
composed of DPPC and MPPC.  The outer leaflet contains DSPE-PEG-2000 which 
depicted by the blue exterior chains.  These components are not displayed to scale. The 
liposomes release interior contents upon exposure to mild hyperthermic temperatures. 
 
2.4.2 Chemokine-loaded TSL 
  The initial liposomal formulation of the chemokine-loaded TSLs paralleled the 
LTSL composition previously used for Doxorubicin delivery (Needham et al., 2001).  By 
employing the REV process, we were able to encapsulate CXCL13 into TSLs with an 
average efficiency of 25%, which is comparable to protein encapsulation for the freeze-
drying methods with many cycles (Colletier et al., 2002).  The CXCL13-loaded TSLs are 
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characterized as shown in Table 1.  The TSLs demonstrated a relatively uniform 
distribution and neutral charge. 
Table 1 Size (nm) Polydispersity index Zeta Potential (mV) 
CXCL13-loaded 
TSLs 
169.3 ± 1.4 0.196 ± 0.011 -0.22 ± 5.22 
 
 
2.5 Discussion 
 Designing TSLs encapsulated with chemokines for a potential cancer 
immunotherapy requires careful examination of the chemokine selection and liposome 
formulation process.  The therapeutic efficacy of delivering chemokines to the tumor site 
as part of an overall strategy to recruit immune cells and bolster the antitumor immune 
response is greatly dependent upon the chemokine selection.  B cells are able to assist the 
antitumor immune response through promoting T cell activity, antibody production, and 
antigen presentation (Restifo et al., 2012; Lei et al., 2015).  However, B cells have been 
underutilized with respect to cancer immunotherapy.  Additionally, higher levels of 
CXCL13 and B cells have correlated with greater survival and prognosis in multiple 
tumor types (Gao et al., 2008).  Based on these observations and the results of the 
transwell migration assay in Figure 2.3, CXCL13 was selected for encapsulation into 
TSLs.  However, it is important to note that the role of chemokines in immunology is 
multifaceted as they can attract multiple immune cell types and have a variety of 
immunological functions.  Therefore, CXCL12 and CCL19 were evaluated because of 
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their ability to also recruit B cells and evidence of positive association with antitumor 
immunity.  Although CXCL13 was ultimately selected for the TSLs, different 
combinations of chemokines should be considered for utilization as potential cancer 
treatment options in the future.  CXCL12 and CCL19 have a similar structure and 
molecular weight as CXCL13 and thus encapsulation within liposomes should be 
possible.  Tumor immunity is complex and varied, so different chemokines may be more 
effective and appropriate for specific tumor types compared to CXCL13.   
 The design process for the chemokine-loaded TSLs required significant 
examination of the current limitations and challenges associated with loading and 
delivery of large biomolecules.  The majority of current therapies that employ 
nanocarriers do so for the delivery of small compounds and there is limited research 
pertaining to delivery of large biomolecules (Zylberberg et al., 2016).  However, REV 
has demonstrated previous success for loading oligonucleotides, roughly 10 kDa in size, 
into liposomes.  Therefore, this technique was adapted for CXCL13 encapsulation in 
TSLs and shown to be successful, with a 25% encapsulation efficiency.  Equally 
important, with a size under 200 nanometers, the CXCL13-loaded TSLs will be able to 
take advantage of the EPR effect and passively localize to tumor sites (Fang et al., 2011).  
The TSL neutral charge indicates that they will be relatively stable in serum (Angelini et 
al., 2013).  Ultimately, this work demonstrates that REV can be employed to encapsulate 
large biomolecules into TSLs, potentially expanding the types of biomolecules which can 
be delivered and utilized as a therapeutic.   
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Chapter 3 TSL optimization 
3.1 Scope 
 This chapter recaps the TSLs optimization process with regards to temperature-
sensitivity and overall stability for in vivo-like (high serum content) conditions.  
Background is provided on the benefits and challenges of liposomal cancer therapeutics.  
The chapter also gives background on lipid components and their impact on liposomal 
stability and ability to release encapsulated solute.  An extensive experimental 
investigation was executed to establish the optimal liposomal composition for the 
chemokine-loaded TSLs with respect to stability and release.  The results demonstrated 
that increasing the amount of PEGylated phospholipid while maintaining the MPPC 
content, yielded liposomes that exhibited sufficient stability in an in vivo-like 
environment while sustaining the ability to release solute upon exposure to mild 
hyperthermic temperatures.      
 
3.2 Background 
3.2.1 Challenges of Liposomes Therapies 
 Careful modifications and considerations must be taken to ensure that liposomes 
are able to translate from the benchtop-in vitro studies to an in vivo environment.  
Liposomes offer many potential advantages for the delivery of cancer therapies.  For 
instance, conventional chemotherapies are often associated with severe toxicity and 
hazardous side effects; therefore, packaging them within a liposome greatly helps to 
mitigate these negative outcomes (Steichen et al., 2013).  Additionally, shielding 
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conventional chemotherapies with a lipid bilayer helps to reduce degradation during 
circulation which can lead to less frequent administration.   
 A major issue that must be addressed when translating liposomal drug carriers to 
an in vivo environment is clearance by the reticuloendothelial system (RES) which is 
comprised of the spleen, kidney, lymph nodes, bone marrow, and liver.  The vast 
majority of systemically administered liposomes accumulate in the liver (Nie 2010).  
Liposomes accumulate in RES organs because they diffuse through pores in the 
microvasculature which can range between 100 to 800 nanometers.  Once trapped at 
these sites, liposomes are phagocytosed by macrophages and additional phagocytic cells 
(Van Etten et al., 1998).  Liposomes can interact with serum proteins during circulation, 
which can destabilize the lipid bilayer (Semple et al., 1998).  Also, serum proteins can 
promote opsonization of the liposomes and clearance from circulation via phagocytosis 
by macrophages (Yan et al., 2005).  In order to address these issues, researchers have 
coated liposomes with PEG chains which has successfully shown to reduce interactions 
with serum proteins and increase circulation time (Suk et al., 2016).  Modulation of these 
components was taken into consideration when optimizing the chemokine-loaded TSLs.  
 
3.2.2 Challenges of TSLs therapies 
 Utilizing TSLs in an in vivo environment presents a new set of challenges.  TSLs 
are composed of phospholipids that have a phase transition temperature a few degrees 
above physiological temperature; therefore, they are inherently leakier than non-TSLs in 
an in vivo environment (Kneidl et al., 2014).  The TSL composition must be carefully 
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balanced so that exposure to mild hyperthermic temperatures sufficiently increases the 
bilayer permeability while still maintaining stability during circulation at physiological 
temperature.  This is a narrow window in which the TSL stability and release must fit.  
Additionally, chemokines are much larger in size than conventional chemotherapies 
which that been delivered in vivo using TSLs.  For comparison, chemokines are roughly 
10 kDa in size compared to Doxorubicin which is roughly 500 daltons.  Due to this 
dramatic size difference, the TSL composition needed to be further evaluated to ensure 
optimal release and stability.  Therefore, multiple iterations of the TSLs were evaluated 
in various amounts of serum proteins to mimic both a cell culture and in vivo 
environment. 
 
3.3 Material and Methods 
3.3.1 CXCL13 Conjugation 
Mouse CXCL13 from Biolegend (San Diego, CA) was conjugated with Alexa Fluor 488 
C5 Maleimide from Thermo Fisher Scientific via thiol maleimide reaction (Waltham, 
MA).  Unconjugated Alexa Fluor 488 C5 Maleimide was separated by extensive dialysis 
using a dialysis tubing with a 1-kDa molecular weight pore size (Billerica, MA).  Thin 
layer chromatography was utilized with methanol and dichloromethane at a 90:10 ratio to 
confirm successful conjugation.  
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3.3.2 Liposome Composition 
Multiple liposome formulations were evaluated in the release studies.  10 kDa fluorescein 
isothiocyanate (FITC) dextran was used as a surrogate for CXCL13 for the initial studies.  
Mouse CXCL13 has a molecular weight of 9.79 kDa.  Therefore, 10 kDa FITC dextran 
was utilized to mimic CXCL13 because of its comparable size and fluorescent properties.  
10 kDa FITC dextran were purchased from Sigma-Aldrich and encapsulated inside the 
TSLs using REV (Natick, MA).  The additional components utilized were cholesterol and 
hydrogenated soy L-α-phosphatidylcholine (HSPC) from Avanti Polar Lipids (Alabaster, 
AL).  The LTSL was composed of molar percentage of 86% DPPC, 10% MPPC, and 4% 
DSPE-PEG-2000.  These liposomes were used for the initial set of release experiments.  
The non-temperature sensitive liposomes (NTSL) had a molar content of 59% HSPC, 
39% Cholesterol, and 2% DSPE-PEG-2000.  The modified LTSL formulation, LTSL-10, 
was composed of 80% DPPC, 10% MPPC, and 10% DSPE-PEG-2000 molar percentage.  
All liposomes were formulated with a lipid-to-solute mass ratio of 40:1.  Alexa Fluor 
488-conjugated CXCL13 were encapsulated into LTSL-10s by REV.  Non-encapsulated 
solute was separated from the TSLs by extensive dialysis at 4 °C using dialysis tubing 
with a 300-kDa molecular weight pore size from Spectrum Labs (Billerica, MA).   
 
3.3.3 Liposomal Release Studies 
The release of 10 kDa FITC dextran and Alexa Fluor 488-conjugated CXCL13 was 
determined by measurements via a Shimadzu RF 5301 spectrofluorophotometer 
(Marlborough, MA).  The fluorescence was measured at excitation and emission 
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wavelengths of 497 nm and 518 nm, respectively.  Liposomes were incubated at 37 °C or 
42 °C in varying amounts of FBS solution (0%, 10% and 50%) for 30 minutes then 
dialyzed in 4 liters of PBS at 4 °C overnight with a 300-kDa molecular weight pore size 
dialysis tubing (Billerica, MA).  This dialysis step was performed to ensure that there was 
separation of released 10 kDa FITC dextran and Alexa Fluor 488-conjugated CXCL13 
from the remaining liposomal solution.  FBS was used to model the serum 
proteins/liposome interactions that would occur in cell culture media and in vivo.  
Additional experiments were carried out in which liposomes were incubated for various 
durations, 5 minutes up to 6 hours, in 10% FBS at 37 °C and then dialyzed in 4 liters of 
PBS at 4 °C overnight.  For each study, fluorescence measurements of the liposomes 
were recorded pre-dialysis and post-dialysis to determine the change in fluorescence 
signal.  This change in signal was utilized to determine the amount of released 10 kDa 
FITC dextran and Alexa Fluor 488-conjugated CXCL13.  Each experimental condition 
was performed in triplicates.  Empty TSLs were also measured to account for background 
signal due to liposomes in the solution.   
 
3.3.4 Statistical Analysis 
The data are presented as mean ± standard deviation of experiments in triplicates. The 
data were analyzed with Welch’s t-test (p-value ≤ 0.05) or with a two-way ANOVA test 
(p-value ≤ 0.05) for comparisons between different liposomal compositions and 
temperatures, and different serum contents and temperatures.  Additional Tukey tests 
were performed to determine which groups had significant differences.   
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3.4 Results 
3.4.1 Evaluating Liposome Temperature-Sensitivity 
 The first step in optimizing the TSLs was to confirm their “temperature-
sensitivity”, meaning that they exhibited greater release of encapsulated solutes when 
exposed to mild hyperthermic temperatures (i.e., 42 °C) compared to physiological 
temperature (i.e., 37 °C).  42 °C was selected to thermally-trigger release of the TSLs 
because it is above the phase transition temperature of DPPC and MPPC.  The initial 
LTSLs were compared to NTSLs to evaluate their release capabilities.  The liposomes 
were tested in serum-free PBS at 37 °C and 42 °C to get a baseline understanding of their 
ability to release 10 kDa FITC dextran.  The initial incubation duration at elevated 
temperatures was 30 minutes, which has been shown to result in near complete release of 
small molecules from LTSLs (Needham et al., 2001).  As shown in Figure 3.1, the 
liposomes consisting of the LTSL composition had a significant increase in 10 kDa FITC 
dextran release when incubated for 30 minutes at 42 °C compared to 37 °C.   
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Figure 3.1. Release of 10 kDa FITC dextran from liposomes.  NTSLs and LTSLs loaded 
with 10 kDa FITC dextran were incubated at 37 °C and 42 °C for 30 minutes in PBS.  
The LTSLs demonstrated a significant increase in the release of 10 kDa FITC dextran 
when incubated at 42 °C compared to 37 °C.  Release of FITC dextran from NTSLs was 
independent of temperature.  (**p <0.01). 
 
  Furthermore, the liposomes composed of the NTSL composition did not show an 
increase in release, signifying that the observed temperature-triggered release could be 
attributed to differences in liposome composition and not the liposome formulation 
process.  The observed 10% release for the NTSLs is likely due to the methodology by 
which the non-encapsulated 10 kDa FITC dextran was separated from the liposomes.  
The liposomes were dialyzed extensively for 48 hours at 4 °C immediately after 
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formulation.  The collected liposomes were incubated and then dialyzed again for 24 
hours at 4 °C.  Between the two dialysis steps, it is likely that a small portion, 5-10%, of 
the 10 kDa FITC dextran leaked out from the liposomes which accounts for this observed 
NTSL release.  In previous studies, LTSLs demonstrated nearly complete release of small 
molecules after 30-minute incubation at 42 °C (Needham et al., 2001).  Therefore, we 
expected a large percentage of entrapped solute to be released from the LTSLs when 
incubated at 42 °C compared to 37 °C after 30 minutes.  However, the LTSLs did not 
completely release under these conditions and this is likely due to the larger size of the 10 
kDa FITC dextran molecules. 
 
3.4.2 Liposomes stability in serum 
 Next, the LTSLs were evaluated in the presence of varying amounts of serum 
proteins to more closely replicate conditions in cell culture and in vivo.  The incubation 
duration was kept constant at 30 minutes.  LTSLs were incubated in 10% or 50% serum 
and evaluated at 37 °C and 42 °C.   NTSLs served as a comparison to determine if serum 
content altered release across incubation temperatures.  As shown in Figure 3.2, exposure 
to greater serum content resulted in an overall increase in the release of 10 kDa FITC 
dextran from LTSLs across both temperatures.  This is consistent with previous research 
detailing that serum proteins contribute to instability of TSLs (Jones & Nicholas, 2002).  
Stability, in this case, being measured by how much is released when incubated at 
physiological temperature.  The NTSLs exhibited slight non-significant increase in solute 
release across incubation temperatures and increasingly serum content.   
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Figure 3.2 10 kDa FITC dextran liposomal release in varying serum content.  NTSLs and 
LTSLs encapsulated with 10 kDa FITC dextran were incubated at 37 °C and 42 °C for 30 
minutes in PBS, 10% serum, and 50% serum.  (A) The NTSLs exhibited minimal, non-
significant (n.s.), changes in release due to temperature or serum content.  (B) The LTSLs 
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demonstrated elevated levels of release due to increased serum content at both 
temperatures. (**p <0.01, ***p <0.001, ****p<0.0001). 
 
 The 10% serum solution is comparable to the serum content used in cell culture 
media.  Therefore, it was important to evaluate the liposomes in this condition as it 
informs about how they will operate with cells.  Comparing the LTSL release in serum-
free PBS versus 10% serum, there was a 20% increase in release at 37 °C but only 5% 
increase at 42 °C.  This result suggest that serum can alter the permeability of LTSLs 
even at 37 °C.  For both 37 °C and 42 °C, there was a roughly 15% increase in 10 kDa 
FITC dextran release from the LTSLs when comparing the 10% serum to 50% serum 
incubation condition.  50% serum is comparable to the level of serum content for in vivo 
circulation.  Therefore, it was pertinent that the TSLs were evaluated in this condition so 
that we could be better informed about their potential in vivo stability.  After 30 minutes 
in 50% serum at physiological temperature, nearly half of the 10 kDa FITC dextran was 
released from the LTSLs.  With this in mind, we sought to alter the liposomal 
composition of the TSLs to ensure that less than 35% of encapsulated solute released 
after 30 minutes at physiological temperature in 50% serum.  
 
3.4.3 TSL comparison in high serum 
 PEGylated phospholipid has been shown to be beneficial for promoting liposome 
stability and reducing serum protein interactions; therefore, LTSLs were created with 
modifications to the amount of PEGylated phospholipid and then evaluated in 50% 
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serum.  As before, TSLs were incubated at 37 °C and 42 °C for 30 minutes.  The new 
liposome composition consisted of 10 % DSPE-PEG-2K compared to 4% in the original 
LTSLs.  The DPPC molar content was reduced to allow for the increase in PEGylated 
phospholipid molar content.  As depicted in Figure 3.3, the LTSLs with 10% DSPE-PEG-
2000, referred to as LTSL-10s, were more stable at physiological temperature, 
demonstrating significantly less 10 kDa FITC dextran release, compared to the LTSLs.  
The LTSL-10s also had the greater release of 10 kDa FITC dextran when incubated at 42 
°C compared to LTSLs.  Because the LTSL-10 demonstrated both improved stability at 
37 °C and release at 42 °C in 50% serum, they were pursued for further experiments.  
 
 
Figure 3.3 Release of 10 kDa FITC dextran from LTSL variants.  LTSL variants loaded 
with 10 kDa FITC dextran were incubated at 37 °C or 42 °C for 30 minutes in PBS 
containing 50% FBS. The LTSL-10s had greater stability, releasing approximately 35% 
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at 37 °C compared to more than 45% released by the original LTSL formulation.  The 
LTSL-10s also showed greater release due to heating.  (**p <0.01, ***p <0.001). 
 
3.4.4 Optimized TSLs in cell culture serum 
 The LTSL-10s were further evaluated in 10% serum content to determine their 
performance in a cell culture environment.  NTSLs were evaluated as a negative control.  
The liposomes were evaluated at 37 °C and 42 °C for 30 minutes.  As demonstrated in 
Figure 3.4, the LTSL-10s exhibited greater 10 kDa FITC dextran release when exposed 
to mild hyperthermic temperatures.  Also in 10% serum, the LTSL-10 had much greater, 
nearly complete, release of 10 kDa FITC dextran compared to the original LTSL 
composition in Figure 3.2.  These results are comparable to previous studies showing 
complete release of small molecules from original LTSLs.  
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Figure 3.4 Release of 10 kDa FITC dextran from NTSL and LTSL-10 in 10% serum.  
NTSLs and LTSL-10s loaded with 10 kDa FITC dextran were incubated at 37 °C or 42 
°C for 30 minutes in PBS containing 10% FBS.  LTSL-10s had significant release of 10 
kDa FITC dextran when exposed to heating compared to physiological temperature and 
compared to NTSLs.  (***p <0.001). 
 
3.4.5. Release kinetics of optimized TSLs 
The liposomes were incubated in 10% serum content, at 37 °C and 42 °C, for 
various durations between 30 seconds and 30 minutes to investigate the release kinetics.  
As seen in Figure 3.5, most of the heat-triggered release, greater than 75%, occurred 
within the first 5 minutes of incubation at 42 °C.  The release was significantly less at 37 
°C, plateauing at about 25% after 10 minutes.  These results suggest that the rapid heat-
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triggered release reported for small molecules is also possible for larger molecules 
(Needham et al., 2001). 
 
 
Figure 3.5 The release profile of 10 kDa FITC dextran from LTSL-10s over 30 minutes.  
LTSL-10s loaded with 10 kDa FITC dextran were incubated at 37 °C or 42 °C for various 
time points over the course of 30 minutes in PBS containing 10% FBS.  Measurements 
were recorded at each time point independently.  A majority of the 10 kDa FITC dextran 
was released from LTSL-10s within 5 minutes at 42 °C.  The release of 10 kDa FITC 
dextran at 37 °C increased slowly over time and plateaued around 25%.  (**p <0.01, 
***p <0.001). 
 
 
47 
 
 
3.4.6 CXCL13 Release from optimized TSLs 
 Next, the release of CXCL13 from the LTSL-10s upon exposure to mild 
hyperthermic temperature in a similar manner as 10 kDa FITC dextran was assessed.  
Alexa Fluor 488-conjugated CXCL13 was utilized to study CXCL13 release.  The LTSL-
10s were incubated at 37 °C or 42 °C for 30 minutes in 10% serum.  As shown in Figure 
3.6, there was increased Alexa Fluor 488-conjugated CXCL13 release when the LTSL-
10s were incubated at 42 °C compared to 37 °C.  Although the total amount released at 42 
°C was less than what was observed for 10 kDa FITC dextran under the same conditions, 
these results confirm that there is temperature-sensitive release of the encapsulated 
CXCL13.  Previous studies have demonstrated that dextran molecules have increased 
permeability across membranes and are more biologically inert compared to globular 
proteins (Venturoli & Rippe, 2005).  Therefore, this may explain the discrepancy 
between the results for 10 kDa FITC dextran and CXCL13.  
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Figure 3.6 Release of Alexa Fluor 488-conjugated CXCL13 from LTSL-10s.  LTSL-10s 
loaded with Alexa Fluor 488-conjugated CXCL13 were incubated 37 °C and 42 °C for 30 
minutes in PBS containing 10% FBS.  There was significant increase in release of Alexa 
Fluor 488-conjugated CXCL13 upon heating compared to physiological temperature.  (*p 
<0.05). 
 
3.4.7 Long-term release of optimized TSLs 
We anticipate that the TSLs will accumulate and remain in the solid tumors over 
several hours due to the EPR effect (Grüll et al., 2012).  This motivated a study of LTSL-
10s release when incubated at 37 °C for longer periods of time.  Both 10 kDa FITC 
dextran and Alexa Fluor 488-conjugated CXCL13 were utilized for this study.  The 
endpoint of 6 hours was chosen based upon the transwell migration assay incubation time 
as we sought to determine the amount of release during this time period.  These 
experiments were carried out in 10% serum to replicate conditions of the transwell 
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migration assay.  As shown in Figure 3.7, the release of 10 kDa FITC dextran was linear 
over the course of several hours.  Similarly, Alexa Fluor 488-conjugated CXCL13 
gradually released over time which was to be expected due to their similar size.  There 
were significant differences at 90 minutes and 6 hours between groups but both follow 
similar release over time.  After the course of 6 hours, the majority of the encapsulated 
Alexa Fluor 488-conjugated CXCL13 and 10 kDa FITC dextran was released from the 
LTSL-10s.  It is possible that the remaining molecules become trapped or associated with 
the lipid bilayer and do not release.  Another possibility is that the remaining 
encapsulated solute releases after this time. 
 
 
Figure 3.7 Long-term LTSL-10 release of 10 kDa FITC dextran and Alexa Fluor 488-
conjugated CXCL13.  LTSL-10s loaded with 10 kDa FITC dextran or Alexa Fluor 488-
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conjugated CXCL13 were incubated at 37 °C up to 6 hours in PBS containing 10% FBS. 
Release measurements were taken at each indicated time point.  Both sets of molecules 
had gradual release over time.  (*p <0.05). 
 
3.5 Discussion 
 The optimization of the liposomal composition was vital for formulating TSLs 
that could be used in subsequent cell culture studies and potential in vivo studies.  The 
original LTSL composition was used as a starting point because of its past success with 
delivery of small molecules.  Although it was successful in the initial PBS tests, the 
LTSLs failed to meet expectations when exposed to varying amounts of serum proteins.  
A direct comparison of LTSLs versus LTSL-10s, in both 10% and 50% serum, showed 
that the latter is both more stable, indicated by releasing less 10 kDa FITC dextran at 37 
°C, and more sensitive to heating, indicated by releasing more 10 kDa FITC dextran at 42 
°C.  The improved stability is due to the increased amount of PEGylated phospholipids in 
the outer lipid leaflet which helps to reduce interactions between the lipid bilayer and 
serum proteins.  This reduction in interactions reduces the likelihood that serum proteins 
will integrate into the lipid bilayer and disrupt its structural integrity leading to release of 
encapsulated solutes.   
 The improved temperature-sensitivity of LTSL-10s can be also be attributed to 
the increase in amount of PEGylated phospholipid.  One study on TSLs has previously 
postulated that the PEGylated phospholipids help stabilize pore openings in the lipid 
bilayer while it is undergoing a phase transition (Chen et al., 2013).  In greater detail, 
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upon heating the lipid bilayer shifts from a more rigid solid phase to more fluid phase 
allowing encapsulated molecules to more easily diffuse through the lipid bilayer.  It is 
hypothesized that during this process the lysolipids (i.e., MPPC), form cylindrical pores 
within the bilayer, which serve as direct channels for the encapsulated solute to escape.  
There is evidence that PEGylated phospholipids act to stabilize these pores allowing for 
greater release (Chen et al., 2013).  The results of LTSL-10s exhibiting greater release at 
42 °C versus original LTSLs provides evidences to this notion that PEGylated 
phospholipids help facilitate the rapid MPPC release.  
 Furthermore, the decision to modify the original LTSL composition occurred after 
taking into consideration the time that we suspect the liposomes would need to circulate 
in vivo and accumulate into the tumor space.  The long-term goal of the chemokine-
loaded TSLs is systemic administration to cancer patients as part of a cancer 
immunotherapy strategy.  The experiments in 50% serum closely resemble the serum 
content in circulation.  Therefore, based on these experiments, we would expect the 
original LTSL to release nearly half of its contents in the span of 30 minutes.  On 
average, it takes approximately less than a minute for blood to circulate throughout the 
body and back to the heart so theoretically the LTSLs would have multiple opportunities 
to reach the tumor site with encapsulated chemokine (Puskas et al., 1996).  However, 
based on previous studies, the efficiency of liposomes to accumulate in tumors is actually 
quite low, less than 10%, and that is after several hours (Lokerse et al., 2016).  With this 
in mind, the amount of chemokine that the LTSLs would be able to deliver to the tumor 
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would be extremely low so the composition was modified in order to design TSLs with 
greater stability at 37 °C in 50% serum. 
 The LTSL-10 exhibited greater stability in 50% serum, releasing less than 35% in 
30 minutes at physiological temperature.  Ideally, at physiological temperature, the TSLs 
would have minimal release.  However, accomplishing this is a difficult trade-off, as 
NTSLs could be used to reduce chemokine release during circulation but they would be 
unresponsive to mild hyperthermic temperatures and unable to be thermally-triggered to 
release at the tumor site.  Additionally, in a cell culture environment as shown in Fig 3.7, 
the LTSL-10s demonstrated gradual release over an extended period of time, which may 
be beneficial for therapies in which sustained release of solute is preferred.  The LTSL-
10s were ultimately chosen based on their ability to maintain sufficient level of stability 
at physiological temperature while at the same time being able to rapidly release upon 
exposure to mild hyperthermic temperatures.  A summary of the 10 kDa FITC dextran 
release capabilities of NTSLs, LTSLs, and LTSL-10s is collected in Table 2.  Moving 
forward, these TSLs were used in subsequent cell culture experiments in Chapter 4.  
 
 Table 2 
Serum 
condition 
Release at 37 °C Release at 42 °C 
 PBS 10% FBS 50% FBS PBS 10% FBS 50% FBS 
NTSL 12.3 % 14.4 % 15.0 % 12.5 % 17.9 % 21.2 % 
LTSL 9.4 % 27.4 % 45.0 % 36.5 % 41.1 % 56.8 % 
LTSL-10 N/A 27.4 % 34.1 % N/A 86.0 % 76.4 % 
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Chapter 4 TSL in vitro evaluation 
4.1 Scope 
 This chapter details the in vitro functional assessment for determining whether the 
chemokine-loaded liposomes were able to recruit immune cells to cancer cells and impact 
cancer cell growth.  Background will be provided on the antitumor immune response with 
emphasis on the immune cell population that is recruited by the chemokine-loaded TSLs.  
This chapter will also highlight the importance of immune cell recruitment to cancer cells 
with respect to generating a sufficient antitumor immune response.  An experimental 
investigation was executed to determine whether the chemokine-loaded TSLs were 
capable of releasing chemokines to recruit immune cells in an in vitro transwell migration 
assay.  Additional experiments evaluated the impact of recruited immune cells via 
chemokine-loaded TSLs on cancer cell growth.  The results revealed that the chemokine-
loaded TSLs were able to release chemokines leading to the recruitment of immune cells.  
Additionally, the experimental results suggest that increased immune cell recruitment via 
chemokine-loaded TSLs hinders cancer cell growth.   
 
4.2 Background 
 The antitumor immune response is intricate process by which the immune system 
is able to recognize and respond to cancer.  Tumor immunology as a whole is a growing 
area of research that is constantly evolving but one consistency in the field is that 
multiple components must operate cohesively to launch an effective antitumor immune 
response.  As previously mentioned, significant resources are being devoted towards 
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modulating T cell activity largely because they are able to directly interact with and kill 
cancer cells (Farhood et al., 2019).  However, the importance of B cells’ role in antitumor 
immunity and relationship with T cells should not be overlooked.  For instance, B cells 
are able to play a vital role in tumor immunity by acting as APCs and have demonstrated 
the ability to recognize dying apoptotic cancer cells (Popi et al., 2016; Hansen et al., 
2001).  B1 cells have been shown to produce IgM antibodies specific for tumor antigens 
(Lei et al., 2015).  Antibody-antigen interactions can initiate the complement immune 
response leading to lysis of targeted cell and can promote additional immune cell types to 
interact with targeted cells.  Additionally, B cells have been shown to express 
CD80/CD86 to promote T cell activation (Restifo et al., 2012).  Based upon previous 
research with CXCL13, we expect that CXCL13 will recruit mostly B cells but also 
additional cells within the PCW cell population such as T cells.  The PCW cell 
population has been shown to be effective in halting cancer growth when incubated with 
cancer cells in a 3D spheroid model (Shibad et al., in revision).   With this in mind, we 
hypothesized that recruiting this cell population via CXCL13 will combat cancer cell 
growth. 
 Moreover, immune cell recruitment is important for establishing an effective 
antitumor immune response.  Solid tumors, as opposed to hematologic tumors, have less 
accessibility, therefore, immune cell recruitment can be challenging (Slaney et al., 2014).  
This is exemplified by CAR T cell therapy, which has had limited success for the 
treatment of solid tumors due to immune cell tumor localization difficulties (D’Aloia et 
al., 2018).  In general, the greater number of activated immune cells that are able to 
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localize to the tumor site, the more robust the antitumor immune response (Gao et al., 
2008).   However, there are some exceptions in which suppressive immune cells can 
inhibit the antitumor immune response or contribute to tumorigenesis and metastasis 
(Qian et al., 2010).  Therefore, careful considerations were taken when selecting the 
appropriate chemokine for designing the chemokine-loaded TSLs in Chapter 2.  Studies 
have shown that increased levels of intratumoral B cells and T cells have a beneficial 
impact on the antitumor immune response.  For instance, researchers reported that among 
colorectal cancer patients, higher levels of CXCL13 correlated with a higher amount of 
TILs, specifically B cells and T cells, and these patients exhibited greater overall survival 
(Bindea et al., 2013).  With this in mind, we hypothesized that by recruiting immune cells 
to colorectal cancer cells in vitro via CXCL13-loaded TSLs, there would be a reduction 
in cancer cell growth similar to the results observed in colorectal cancer patients.  
 
4.3 Material and Methods 
4.3.1 Liposome Preparation. 
The liposome used for these experiments was composed of a molar percentage of 90% 
DPPC, 10% MPPC, and 10% DSPE-PEG-2000.  The liposomes were generated using 
REV and non-encapsulated CXCL13 was separated from the liposomes by extensive 
dialysis at 4 °C for 48 hours in 4 liters of PBS with 300 kDa molecular weight pore size 
dialysis tubing (Billerica, MA).  The volume was changed once after 24 hours.  As 
previously detailed, encapsulation of CXCL13 was determined using CBQCA Protein 
Quantitation Kit purchased from Thermo Fisher Scientific (Waltham, MA).   
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4.3.2. Transwell Migration and Co-Culture Assay. 
As described in Chapter 2, mouse PCW cells were collected by injecting 10 ml of HBSS 
with 2% FBS into the peritoneal cavity (Ray et al., 2010).  Murine colon adenocarcinoma 
(MC38) cells were engineered to express TdTomato (Tdt) fluorescent protein and were 
maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 10% FBS, and 1% 
penicillin/streptomycin.  Transwell migration assays with PCW cells were performed in 
10% serum-containing media with a concentration of 0.3 ug/ml of CXCL13 as this has 
been established to be the optimal concentration for attracting B cells.  PCW cells were 
loaded into the top transwell inserts while the bottom transwell chambers were incubated 
with media alone, empty liposomes, CXCL13-loaded TSLs, or free CXCL13.  The 
transwell plate was incubated for 6 hours at 37 °C as this was the established optimal 
incubation conditions for the assay.  Migrated cells were imaged and counted using the 
Nexcelom Celigo microwell plate imager (Lawrence, MA).   
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Figure 4.1 The experimental set up for the co-incubation assay.  MC38-Tdt cells were 
seeded onto the bottom transwell chambers for 24 hours.  Then immune cells were loaded 
into the top transwell insert and the bottom transwell chamber solutions was changed to 
media, empty TSLs, CXCL13-loaded TSLs, or free CXCL13.  The schematic 
demonstrates how CXCL13 is release and induces immune cell recruitment to the MC38-
Tdt cells.  
 For the co-culture assay, 5,000 MC38-Tdt cells in DMEM with 10% serum were 
seeded on the bottom transwell chambers for 24 hours prior to performing the transwell 
migration assay as depicted in Figure 4.1.  On the day of the experiment, the media was 
replaced with each treatment condition, media alone, empty liposomes, CXCL13-loaded 
TSLs, or free CXCL13, and the transwell inserts containing PCW cells were placed on 
top of the transwell plate.  Each incubation condition also contained the equivalent 
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amount of 10% serum-containing media.  After incubating for 6 hours, the transwell 
inserts were removed and the combination of transmigrated PCW cells and MC38-Tdt 
cells were co-cultured for an additional 24 hours.  Images were taken with Keyence 
Fluorescence Microscope BZ-X800 using 4X and 10X objective lens before migration, 
immediately after migration, and 24 hours after migration.  The number of MC38-Tdt 
cells in each of the images was counted using the Keyence BZ-X Analyzer (Woburn, 
MA). 
 
4.3.3 Statistical Analysis 
The data are presented as mean ± standard deviation of experiments in triplicates. The 
data were analyzed with Welch’s t-test (p-value ≤ 0.05). 
 
4.4 Results  
4.4.1 CXCL13-loaded TSLs induce cell migration 
We were interested in determining whether the CXCL13-loaded TSLs were able 
to promote immune cell migration.  Transwell migration assays using freshly collected 
mouse PCW cells were performed to evaluate the ability of the liposomes to release 
chemokine and promote immune cell migration.  The temperature-sensitivity aspect of 
the liposomes was not evaluated in this experiment as we were simply interested in 
determining of the CXCL13-loaded TSLs were able to promote immune cell recruitment.  
An equivalent amount of CXCL13 was administered as free CXCL13 or loaded into 
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liposomes.  Empty liposomes served as a control to determine whether immune cells 
were attracted to the liposomes alone.  Images of the transmigrated immune cells were 
taken after incubation (Figure 4.2).   
 
 
 
Figure 4.2 Images of transmigrated immune cells.  Transwell migration assays were 
performed with media alone, empty liposomes, CXCL13-loaded liposomes, or free 
CXCL13.  Images were recorded to determine the impact of each conditions are 
promoting immune cell recruitment. 
 
 
As seen in Figure 4.3, there was significant immune cell migration among wells 
containing CXCL13-loaded TSLs or free CXCL13 compared to media alone or empty 
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liposomes.  The increase in transmigrated immune cells among wells incubated with 
CXCL13-loaded liposomes compared to empty liposomes suggests that the loaded 
liposomes were able to release a sufficient amount of CXCL13 to generate a chemokine 
gradient and promote immune cell recruitment.  The few transmigrated immune cells 
among wells incubated with media alone or empty liposomes were likely less than five 
microns in diameter, the pore size of the transwell inserts, which allowed them to fall 
through the inserts and settle to the bottom transwell chamber.   
 
Figure 4.3 Transwell migration of immune cells induced by CXCL13.  PCW cells 
were plated in the transwell insert and incubated with media alone, empty TSLs, 
CXCL13-loaded TSLs, or free CXCL13 for 6 hours. The number of transmigrated cells 
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was recorded. The CXCL13-loaded TSLs and free CXCL13 induced greater immune cell 
migration compared to media alone or empty TSLs. (*p <0.05, **p <0.01). 
 
Furthermore, the wells incubated with free CXCL13 exhibited the largest amount 
of immune cell recruitment.  Although an equal initial amount of CXCL13 was 
administered as free chemokine or loaded into liposomes, based on Figure 3.7, at the end 
of the 6-hour incubation period the liposomes released about 70% of their loaded 
CXCL13.  Therefore, the amount of released CXCL13 was not equivalent for both 
conditions and the CXCL13-loaded TSLs did not induce as much immune cell migration.  
This result can also be attributed partly due to the fact that the free CXCL13 is accessible 
to the immune cells throughout the entire incubation period, while the CXCL13 loaded 
into the liposomes is gradually released during this time.  
 
4.4.2 Cancer cell growth reduced by CXCL13-loaded TSLs 
The transwell migration assay with the addition of cancer cells on the bottom of 
the transwells was performed to assess the impact of recruited immune cells via 
CXCL13-loaded TSLs on cancer cell growth.  Initially, MC38-Tdt cells were incubated 
with empty liposomes, CXCL13-loaded TSLs, or free CXCL13, without the addition of 
PCW cells to the upper transwell insert, and monitored over several days.  There was no 
significant difference in cancer cell growth after 24 hours between all conditions 
suggesting that the liposomes and CXCL13 alone do not directly impact cancer cell 
growth (Figure 4.4).   
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Figure 4.4 Growth of MC38-Tdt cells incubated directly with TSLs and CXCL13.  
MC38-Tdt cells were co-incubated directly with media alone, empty TSLs, CXCL13-
loaded TSLs, or free CXCL13 for 24 hours. The number of MC38-Tdt cells was recorded 
and there was no significant difference across all conditions. 
 
This experiment was repeated with the addition of PCW cells to the upper 
transwell insert microscope images were taken to track the growth of the MC38-Tdt cells 
(Figure 4.5).  The TdTomato expression allowed for distinguishing the MC38 cells from 
the recruited immune cells in the bottom transwell chambers.  There was less cancer cell 
growth over time among wells incubated with CXCL13-loaded TSLs or free CXCL13 
compared to media alone or empty liposomes (Figure 4.6).   
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Figure 4.5 10X microscopic images of co-incubated MC38-Tdt cells and immune cells 
after 24 hours.  The bright field images display both the MC38-Tdt cells and recruited 
immune cells.  The MC38-Tdt cells can be identified in the fluorescent red images and 
help to differentiate them from the recruited immune cells. The images are representative 
of triplicate wells. 
 
 
 
 
Figure 4.6 Growth inhibition of MC38-Tdt cells by transmigrated immune cells.  Immune 
cells were plated in the transwell inserts and incubated on top of transwell chambers, 
containing MC38-Tdt cells, with media alone, empty TSLs, CXCL13-loaded TSLs, or 
free CXCL13 for 6 hours.  The number of MC38-Tdt cells after 24-hour co-culture with 
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transmigrated immune cells was recorded.  Wells administered with CXCL13-loaded 
TSLs or free CXCL13 showed a significant reduction in cancer cell growth compared to 
media and non-significant reduction compared to empty TSLs. (*p <0.05). 
 
 
 
This reduction in cancer cell growth is likely due to the increased number of 
transmigrated immune cells that are recruited via CXCL13.  This in vitro experimental 
setup exemplifies the potential of the CXCL13-loaded TSLs as a strategy for limiting 
cancer growth.  These results are in good agreement with the findings in the previous 
report on CXCL13’s importance within the tumor microenvironment and its role in 
promoting immune cell tumor recruitment and decreased cancer growth (Bindea et al., 
2013). 
 
4.5 Discussion 
 Theses sets of experiments were critical to assessing the functionality of the 
CXCL13-loaded TSLs with respect to recruiting immune cells and having a therapeutic 
impact on reducing cancer cell growth.  In Chapter 3, we established that the TSLs were 
capable of releasing CXCL13 but had yet to confirm whether the released chemokines 
were still functionality after liposomal encapsulation.  These transwell migration assays 
confirm that the liposomes are capable of releasing functional chemokine as exhibited by 
their ability to promote immune cell migration.  
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 Despite the fact that the CXCL13-loaded TSLs did not induce as much immune 
cell migration compared to an equivalent amount of free CXCL13, its packaging within a 
liposome still offers multiple advantages for in vivo applications.  For instance, one major 
benefit of liposomal CXCL13 over free CXCL13 is that while it is encapsulated inside 
the lipid bilayer it can better avoid clearance by the RES (Suk et al., 2016).  Although 
there is limited information on the plasma half-life of administered chemokines, there has 
been studies on cytokines which are comparable.  The cytokine Interleukin-2 (IL-2) has 
been developed and modified for therapeutic use for treating metastatic melanoma.  
Researchers have determined that it has a plasma half-life of approximately 4 minutes 
when administered intravenously to mice (Donohue et al., 1983).  IL-2 has a molecular 
weight of 13-15 kDa and is comprised of alpha helices similar to CXCL13, which has 
one alpha helix and a beta sheet.  Therefore, we hypothesize that CXCL13 would have a 
comparable plasma half-life to that of IL-2 and would be cleared from circulation on the 
scale of minutes.  This is a topic that is further explored in Chapter 5.  
 Furthermore, we also attempted to perform transwell migration assays comparing 
heated and unheated CXCL13-loaded TSLs.  Prior to the transwell migration assay, 
CXCL13-loaded TSLs were incubated at 37 °C or 42 °C for 30 minutes then added to the 
bottom transwell chambers.  We initially hypothesized that the heated CXCL13-loaded 
TSLs would induce more immune cell migration.  However, based upon the experiments 
in Chapter 3, specifically Figure 3.7, we determined that the amount of released CXCL13 
was comparable in both conditions at the end of the transwell migration assay.  
Incubating the CXCL13-loaded TSLs at 42 °C for 30 minutes resulted in 55% CXCL13 
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release.  The transwell plate was incubated at 37 °C for a total of 6 hours.  Based on 
Figure 3.7, incubating the TSLs at 37 °C for 6 hours resulted in 70% release of 
encapsulated CXCL13.  Therefore, for this experiment there was no significant difference 
in immune cell migration because by the end of the assay there was an equivalent amount 
of release CXCL13 in both conditions.  However, it is possible that if a shorter incubation 
time was used there may have been a difference in immune cell recruitment between the 
heated and unheated CXCL13-loaded TSLs.  Although there was no distinguishable 
difference between the heated and unheated CXCL13-loaded TSLs in our in vitro 
experimental setup, the temperature-sensitivity aspect of the liposomes can be exploited 
in vivo. 
 Packaging CXCL13 in TSLs should increase circulation time for the chemokine, 
which in principle will increase the amount that reaches the tumor compared to free 
chemokine.  This is evaluated in the next chapter.  Medical practitioners can use HIFU to 
selectively heat the tumor regions and trigger the accumulated TSLs to release CXCL13.  
Additionally, as shown in Figure 3.7, the CXCL13-loaded TSLs are capable of releasing 
gradually over time at physiological temperature.  Therefore, the CXCL13-loaded TSLs 
that accumulate in the tumor space can release CXCL13 without needing heating and 
induce sustained immune cell recruitment to the tumor site if that is preferable for 
different tumor types rather than a bolus release.  
 Both CXCL13-loaded TSLs and free CXCL13 inhibited cancer growth at a 
comparable level in the in vitro studies performed with MC38-Tdt cells.  The immune 
cells that are recruited by the CXCL13 are most likely B cells and T cells which as 
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detailed before have multiple mechanisms by which they can contribute to the antitumor 
immune response.  For example, the recruited B cells may stimulate T cell activity or 
phagocytose dying cancer cells and present antigens to the recruited T cells which act 
directly to kill the cancer cells.  In future studies, the mechanisms by which the recruited 
immune cells are able to limit MC38-Tdt cell growth should be further explored.   
 As shown in Figure 4.3, free CXCL13 recruits significantly more immune cells 
than CXCL13-loaded TSLs.  Therefore, we expected that free CXCL13 would cause 
more cancer cell growth inhibition.  However, this was not the case as seen in Figure 4.6 
which means that there is a limit to the impact of immune cell recruitment on cancer cell 
growth.  Immune cell recruitment is just one step in the multiple step process of the 
antitumor immune response.  The two additional processes necessary for generating an 
effective antitumor immune response are immune cell activation and tumor cell 
recognition.  The CXCL13-loaded TSLs have demonstrated the ability to recruit immune 
cells, but that not does not necessarily mean that the recruited immune cells are activated 
or able to recognize the MC38-TdT cells.  We hypothesize that this therapeutic approach 
would have greater efficacy in combating tumor growth by coupling CXCL13 with 
additional immunomodulatory factors.  For instance, the CXCL13-loaded TSLs would be 
combined with an immunostimulatory factor or tumor associated antigen.  This topic of 
improving the efficacy of CXCL13-loaded TSLs for combating cancer growth will be 
expanded upon in Chapter 6. 
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Chapter 5 Evaluation of CXCL13 in vivo 
5.1 Scope 
 This chapter describes the preliminary experiments necessary for translating the 
CXCL13-loaded TSLs into an in vivo model.  This chapter will detail the challenges of 
chemokine-based therapies.  In addition, background will be provided on the role of TILs 
with respect to tumor immunity.  An experimental investigation was undertaken to 
evaluate the plasma half-life of systemically administered CXCL13 in mice.  Also, the 
impact of injections of free CXCL13 to melanoma tumors in a syngeneic mouse model 
was assessed.  The results demonstrated that CXCL13 is fast-acting, possessing a plasma 
half-life on the scale of minutes.  Also, the results provide evidence that CXCL13 
administration to tumors can have a therapeutic impact on combating tumor growth.  
 
5.2 Background 
5.2.1 Challenges of chemokine-based therapies 
 Chemokine-based therapies not only improve immune cell recruitment, but also 
can improve the efficacy of existing cancer treatments.  For instance, the overall 
effectiveness of conventional chemotherapies can benefit from the addition of 
chemokines.  Conventional chemotherapies aim to promote cancer cell death, and in 
doing so, can initiate several antitumor immune responses (Galluzzi et al., 2015).  For 
instance, anthracyclines such as Doxorubicin can drive cancer cells to undergo autophagy 
leading to the recruitment and stimulation of phagocytic immune cells (Michaud et al., 
2011).  These phagocytic immune cells can localize to lymph tissues and present tumor 
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antigens to T cells leading to a more robust T cell-mediated antitumor immune response.  
Additionally, several chemotherapies such as Vemurafenib have been associated with 
increasing the amount of TIL T cells (Cooper et al., 2013).  The addition of a chemokine, 
would further enhance the recruitment of immune cells to the tumor site and lead to a 
more effective cancer treatment.  Therefore, researchers have tested chemokine-based 
therapies in combination with conventional chemotherapies.  For example, studies have 
looked at the combinatorial effects of administering CXCL10 and cisplatin for the 
treatment of solid tumors (Li et al., 2005).  They found that CXCL10 and cisplatin 
together were more effective in suppressing tumor growth and elongating survival time 
than either alone in Lewis lung cancer and colon adenocarcinoma mouse tumor models.  
As previously mentioned, emerging cancer immunotherapies such as cell-based therapies 
would also benefit from leveraging chemokines to enhance the number recruited 
activated immune cells to the tumor site.  Additionally, chemokine-based therapies are in 
development as standalone treatments.  For instance, administration of CCL21 for lung 
cancer resulted in enhanced leukocyte tumor infiltration and reduced immunosuppressive 
cells (Kar et al., 2011).  Overall, chemokine-based therapies can be effective alone or to 
bolster existing cancer treatments. 
 However, there are several challenges to chemokine-based therapies.  For 
instance, as with all cancer immunotherapies, modulating the immune system can lead to 
dangerous inflammatory side effects.  Additionally, chemokines are severely limited by 
their extremely short plasma half-lives (Mohit et al., 2012).  As previously mentioned, 
the cytokine IL-2 has a similar structure as chemokines and a plasma half-life of only 4 
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minutes (Donohue et al., 1983).  Free chemokines as a therapeutic are hindered by rapid 
plasma half-life, and therefore, require further modification such as conjugation with 
PEG chains.  However, these chemical modifications can alter the physiochemical 
properties of the chemokine and impact function (Damodaran et al., 2010).  Alternatively, 
chemokines can be packaged within liposomes as detailed in this thesis.  
 
5.2.2 Role of intratumoral immune cells 
 There is growing research being focused on the tumor immune microenvironment 
and the complicated interplay between the two systems.  The tumor immune cell 
population is an important component of tumor immunology and can assist or impede 
tumor progression.  For example, increased levels of TIL Regulatory T (Treg) cells have 
been found to be associated with tumor progression for ovarian cancer and lung cancer 
(Chaudhary et al., 2016).  Treg cells can promote a more immunosuppressive tumor 
microenvironment.  Additionally, tumor-associated macrophages can promote inhibition 
of the antitumor immune response and degradation of the surrounding extracellular 
matrix to promote tumor metastasis (Yang et al., 2017).    
 In contrast, immune cells can combat tumor progression through multiple 
immunological mechanisms as detailed in Chapter 1, and in many cases, a greater 
number of TILs has generally correlated with better prognosis (Gao et al., 2008).  One 
study in particular analyzed the TIL population across colorectal cancer patients.  The 
study analyzed the gene expression of patients’ tumor cells as well as immune cells in the 
tumor microenvironment to gain insight into the interaction between the two.  The study 
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found that higher levels of CXCL13 expression in tumor cells were correlated with more 
intratumoral B cells, helper T cells and cytotoxic T cells, as well as prolonged disease-
free survival time (Bindea et al., 2013).  Additional experiments in a mouse colorectal 
cancer model demonstrated that direct CXCL13 administration into the colonic 
submucosa near the tumor resulted in decreased tumor growth.  These findings suggest 
that CXCL13 within the tumor microenvironment improves immune cell tumor 
localization and that its administration helps inhibit tumor growth.   
 
5.3 Material and Methods  
5.3.1 CXCL13 administration and serum detection 
Wild-type mice on a C57BL/6 background were administered 1 microgram of free 
CXCL13 or CXCL13-loaded TSLs via tail vein injection.  The mice were bled at 1, 5, 
and 30 minutes after injection by cardiac puncture and the collected serum was allowed 
to incubate for 2 hours at room temperature to ensure blood clotting.  A single mouse was 
utilized for each time point to avoid repeated bleedings.  Serum samples were spun at 
10,000 rpm for 30 minutes and the supernatant was collected.  The collected samples 
were diluted 1:5 and the amount of CXCL13 was measured using the Mouse 
CXCL13/BLC/BCA-1 Quantikine ELISA Kit from R & D Systems (Boston, MA).  
Known quantities of mouse CXCL13 were used to establish a standard curve and 
determine the amount of CXCL13 that was in the serum at each time point.  The plasma 
half-life of CXCL13 was estimated by plotting the amount of detected plasma CXCL13 
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over time and calculating the time it took for CXCL13 to reduce to half of its amount 
between 1 minute and 5 minutes.  These time points were within the linear range.  
  
5.3.2 Mouse B16F10 tumor studies 
Immunocompetent wild-type mice on a C57BL/6 background were bred in the animal 
facility at Boston University School of Medicine.  The Institutional Animal Care and Use 
Committee of the Boston University School of Medicine approved procedures involving 
animal use.  A syngeneic mouse tumor model was established by inoculating mice with 
250,000 B16F10 mouse melanoma cells on their right flank on the initial date of the 
tumor monitoring experiments.  On this day (Day 0), mice were stratified into two 
groups; those that were administered 1 microgram of CXCL13 or saline.  For the initial 
set of experiments, the mice were also administered 1 microgram of CXCL13 or saline 
near the tumor site on days 4, 6, 8, 11, and 13 after tumor cell inoculation.  This initial 
experiment concluded on Day 19.  In a subsequent experiment, two groups of mice were 
administered 1 microgram of CXCL13 or saline on days 0, 4, 6, 8, and the experiment 
concluded on Day 16.  The volume used for all injections near the tumor site was 10 
microliters.  An additional experiment was performed in which tumors were injected on 
days 0,4,6,8, 11, 13, 15, and 17 and harvested on day 18 for flow cytometry analysis.  
The tumors were monitored daily and size was measured with calipers.  On the endpoint 
day, the tumors were excised and weighed.   
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5.3.3 Tumor Digestion and TILs analysis 
 After tumors were isolated they underwent further processing to isolate the TILs.  
The tumors were minced with a surgical blade and incubated at 4 °C for 40 minutes in a 
digestion buffer composed of 100 U/ml of Collagenase IV in RPMI media, 20 mM 
HEPES buffer, and 100 ug/ml of DNase I.  The Collagenase IV and DNase I were 
purchased from Worthington Bio and Alfa Aesar, respectively (Lakewood, NJ; Wardhill, 
MA).  The tumors were digested to facilitate degradation of any extracellular matrix and 
other connective tissues.  Then 10 ml of FACS buffer (1X DPBS + 1% FBS + 0.2 mM 
EDTA) was added and the solution was passed through a 70-micrometer filter and spun 
at 1200 rpm to pellet the cells.  The cells were washed again with FACS buffer and re-
spun.  Next, the cells were suspended in 40% Percoll in RPMI media and then under laid 
with 80% Percoll in RPMI media.  The Percoll was procured from GE Life Sciences 
(Marlborough, MA).  This 40%-80% discontinuous gradient solution was spun at 2000 
rpm for 25 minutes which allowed separation within the solution so that the lymphocytes 
settled in the middle layer of the solution.  This middle layer was carefully collected and 
stained as previously described with a couple of adjustments (Lee et al., 2015).  Notably, 
B220 was replaced with CD45 and Ghost Dye Violet 510 staining was used to identify 
live cells.  Otherwise, the antibody panel was the same as the panel used in Chapter 2 for 
the staining of migrated PCW cells.  The CD45 PerCp Cy5.5 antibody and Ghost Dye 
Violet 510 were purchased from BD Biosciences and Tonbo Bioscience, respectively 
(San Jose, CA; San Diego CA). 
 
75 
 
 
5.3.4 Statistical Analysis 
The free CXCL13 half-life experimental data are presented as mean ± standard deviation 
in triplicates and were analyzed with Welch’s t-test (p-value ≤ 0.05).  The tumor studies 
and TIL profiles are presented as mean ± standard deviation in triplicates and were 
analyzed with Welch’s t-test (p-value ≤ 0.05).   
 
5.4 Results 
5.4.1 CXCL13 plasma half-life study 
 The length of time that CXCL13 is able to remain in circulation is important for 
better understanding of how the CXCL13-loaded TSLs will operate if they are 
systemically administered.  Therefore, mice were injected with a single dose of CXCL13 
via tail vein injection and then bled at various time points.  The amount of CXCL13 in 
the mouse serum was detected via ELISA measurements.  As seen in Figure 5.1, the 
majority of CXCL13 when it is administered freely is cleared from circulation within 5 
minutes after injection.  The plasma half-life was roughly estimated to be 3.84 minutes 
based upon the difference in amount of plasma CXCL13 between 1 minute and 5 
minutes.  The level of serum CXCL13 drops to roughly 10% of the initial administered 
dose within 5 minutes.  In contrast, when CXCL13 was administered encapsulated within 
TSLs, the plasma half-life was extended to 23.90 minutes.  Therefore, the TSLs improve 
the circulation time of CXCL13 which is consistent with previous literature on 
PEGylated liposomes (Suk et al., 2016).  Additional studies with the CXCL13-loaded 
TSLs must be performed to established statistical significance.  
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Figure 5.1 The serum levels of injected CXCL13 into mice over time.  Mice were 
injected with 1 microgram of CXCL13 as free chemokine (n=3) or encapsulated into 
TSLs (n=1) and then bled at designated time points.  The values for CXCL13 were 
normalized to the initial amount of injected CXCL13.  The levels of CXCL13 drastically 
fell within 5 minutes after injection for the non-encapsulated CXCL13.  In contrast, 
encapsulated CXCL13 had improved serum levels over time.  
 
5.4.2 CXCL13 delays tumor growth 
Prior to utilizing the CXCL13-loaded TSLs to combat cancer growth, it was important to 
determine whether free CXCL13 had a therapeutic effect on tumor growth.  Therefore, 
CXCL13 was injected near the tumor site and the tumor size was tracked over several 
days to monitor growth.  As demonstrated in Figure 5.2, in the initial sets of in vivo 
experiments, the mice administered with CXCL13 showed a delayed growth in tumors 
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over two weeks compared to control mice administered with saline.  On Day 13 after 
tumor cell inoculation, the mice injected with saline had noticeable measurable tumors 
while the mice injected with CXCL13 did not.  At this point the mice were monitored 
daily and received no additional injections.  The control mice continued to exhibit tumor 
growth each day while all the mice, except one, that had been previously administered 
CXCL13 failed to show noticeable tumor growth up until Day 19.  This experimental 
mouse’s tumor was much smaller compared to the control mice.  Small tumors were 
discovered in mice administered with CXCL13 only after the mice were operated on.  
Therefore, these results suggest that the administration of CXCL13 delays tumor growth.  
Due to technical challenges, multiple control mice were sacrificed beforehand, on Day 15 
and Day 18, so we were unable to accurately compare the tumor endpoint masses for all 
mice on Day 19.  However, as shown in Figure 5.3, the control mice had larger tumors 
than mice administered CXCL13.  
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Figure 5.2 B16F10 tumor size was tracked over time between mice administered with 
saline or CXCL13.  Mice were inoculated with B16F10 cells and injected with saline 
(n=3) or CXCL13 (n=4) near the tumor site.  The tumor sizes were monitored and 
measured over time using calipers.  Mice administered with CXCL13 demonstrated less 
tumor growth over time compared to mice administered with saline.  Three of the mice of 
the mice administered with CXCL13 did not appear to have tumor growth by Day 19. 
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Figure 5.3 The endpoint tumor masses between mice administered with saline (n=3) or 
CXCL13 (n=4) after 19 days.  Mice were sacrificed on Day 19 after initial tumor 
inoculation with B16F10 cells and their tumors were weighed.  The two saline mice with 
larger tumors were sacrificed earlier due to technical difficulties, on Day 15 and 18, 
respectively.  Mice administered with CXCL13 on average had smaller tumors with a p 
value equal to 0.259. 
 
 An additional experiment was performed to more accurately determine whether 
there was a difference between the endpoint tumor masses of mice administered with 
CXCL13 or saline.  As shown in Figure 5.4, the endpoint masses of the tumors belonging 
to control mice were heavier, indicating greater growth, than the tumors of mice 
administered with CXCL13.  These results are in good agreement with the previous in 
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vivo experiment in which CXCL13 showed a therapeutic impact on delaying tumor 
growth.  
 
Figure 5.4 The endpoint tumor masses were assessed between mice administered with 
saline (n=4) or CXCL13 (n=4) after 16 days.  Mice were inoculated with B16F10 cells, 
administered with saline or CXCL13, and then sacrificed on Day 16.  The tumor weights 
were measured and mice administered with CXCL13 had smaller tumors compared to 
saline with a p value equal to 0.065. 
 
5.4.3 Intratumoral immune cell analysis 
 Furthermore, we sought to gain better insight on the impact of CXCL13 on the 
tumor immune cell population.  We hypothesized that locally administrating CXCL13 to 
the tumor site would increase the number of recruited immune cells as seen in the in vitro 
experiment.  Tumors were digested and their TILs were isolated and stained with 
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multiple markers to determine the immune cell populations between tumors administered 
with CXCL13 or saline.  The gating strategy used to profile the immune cells is depicted 
in Figure 5.5.   
 
Figure 5.5 The flow cytometry panels depicting the gating strategy for TILs.  TILs were 
isolated and stained with various surface markers.  Mouse PCW cells were utilized as a 
control to establish the population gating.  The CD45+ cells were first selected to 
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separate out the tumor cells and then the total lymphocyte population was identified.  
These cells were further stratified as B cells (CD19+ CD5-) and T cells (CD19- CD5+).  
 
As shown in Figure 5.6, there was a greater percentage of total lymphocytes and TIL T 
cells among tumors that had been administered with CXCL13 compared to saline.  There 
was also a slight an increase in the percentage of TIL B cells in the tumors of mice 
injected with CXCL13.   
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Figure 5.6 TIL profile between mice administered with saline (n=3) or CXCL13 (n=3).  
Tumor cells belonging to mice administered saline or CXCL13 were stained with various 
surface markers to identify lymphocytes and B cell and T cells. (A) The percentage of 
lymphocytes in the tumors administered with CXCL13 was increased compared to saline 
with a p value equal to 0.169.  (B) There was a small increase in the percentage of TIL B 
cells in CXCL13-treated tumors with a p value equal to 0.822. (C) TIL T cell percentage 
was increased in tumors administered with CXCL13 with a p value equal to 0.145. 
 
5.5 Discussion  
 These preliminary results in Figure 5.1 are important for setting the groundwork 
for employing CXCL13-loaded TSLs for in vivo applications in an effort to combat 
tumor growth.  The evaluation of CXCL13’s plasma half-life was a necessary step 
towards understanding how the CXCL13-loaded TSLs will operate in vivo.  The results 
demonstrate that free CXCL13 is rapidly cleared making it a challenge to be used as a 
cancer therapy.  Also, these results are in good agreement with previous studies detailing 
the short plasma half-lives of cytokines.  With a plasma half-life of under 5 minutes, if 
free CXCL13 is administered via intravenous injection the vast majority will be cleared 
before they can accumulate in the tumor site.  Therefore, they will be ineffective in 
recruiting immune cells to the tumor site.  
 Overall, this makes a strong argument for packaging CXCL13 inside liposomal 
carriers such as our TSLs.  Furthermore, in these preliminary in vivo experiments the 
CXCL13-loaded TSLs successfully increased the plasma half-life of CXCL13 from under 
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5 minutes to over 20 minutes.  This is consistent with previous research in which 
PEGylated liposomes have been demonstrated to improve the plasma half-life of small 
molecules such as Doxorubicin and have been shown to circulate for many hours 
(Gabizon et al., 2003b).  The longer that CXCL13 remains in circulation the greater 
likelihood that it will passively localize and accumulate to the tumor site over time due to 
the EPR effect.  Therefore, we hypothesize the CXCL13-loaded TSLs will result in 
greater likelihood of CXCL13 accumulation in the tumor space.  As previously discussed, 
short plasma half-life is not only an issue for CXCL13 but also for other chemokines 
(Mohit et al., 2012).  The TSLs designed in this work can be employed to deliver 
additional biomolecules to improve their plasma half-life and potentially benefit 
chemokine and cytokine-based therapies. 
 Additionally, directly injecting CXCL13 near tumor sites was important for 
determining whether CXCL13 has a therapeutic impact on tumor growth.  One of the 
biggest challenges for testing the efficacy of a therapy is establishing an optimal dosing 
regimen.  This was particularly difficult for CXCL13 as currently there is very limited 
information of chemokines or cytokines as a therapeutic option.  Also, the response for a 
chemokine, induced cell migration, is vastly different than a conventional chemotherapy 
which can be assessed by its ability to kill cancer cells.  For a chemokine-based therapy, 
the expected effect is increased immune cell recruitment to the tumor site but the 
magnitude of that response needed to impact tumor growth is unknown.   
 Therefore, multiple trials were performed to determine the optimal number of 
injections and amount of injected CXCL13 necessary to have an impact on tumor growth.  
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Initially, mice were injected once with CXCL13 in the 100s of nanogram range, a dosage 
similar to that used for the in vitro transwell migration assay, but there was no impact on 
tumor growth.  There are a number of differences between the transwell setup and the in 
vivo environment.  In the transwell set up, the immune cells were in close proximity to 
the chemokine and were more easily able to migrate because they did not need to 
undergo any extravasation process as they would in vivo.  Also, CXCL13 likely degrades 
much faster when it is injected in vivo compared to sitting in the transwell.  This resulted 
in the decision to increase the amount of administered CXCL13 to 1 microgram and 
inject on Day 0 to help initiate recruitment of immune cell immediately prior to tumor 
establishment.   
 Additional injections were carried out to ensure that there was a sufficient amount 
of CXCL13 and immune cell recruitment at the tumor site throughout the tumor growth 
process.  Additional experiments were performed with no initial administration of 
CXCL13 on Day 0 but there was no difference in tumor growth compared to control 
mice.  This suggests that the initial CXCL13 is important for ensuring immune cells are 
recruited immediately following tumor cell inoculation.  As shown in Figure 5.2, 
CXCL13 was successful in delaying tumor growth but not entirely preventing its 
formation.  In this initial experiment, CXCL13 injections stopped after Day 13 but it is 
possible that if CXCL13 was continued to be administered then tumor growth may have 
been inhibited to an even greater extent.  However, the fact that the mice administered 
with CXCL13 eventually exhibited tumor growth suggest that CXCL13 alone is not 
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effective for complete inhibition of tumor growth.  In Chapter 6, we will postulate on 
further strategies for improving the effectiveness of the CXCL13-loaded TSLs.  
 Additionally, tumor analysis revealed that CXCL13 acted to recruit more overall 
lymphocytes, B cells, and T cells to the tumor.  However, the amount of increase was not 
significant and across the board there was a small number of TILs for both conditions.  
This may be explained the tumor model used for these sets of experiments.  B16F10 cells 
are less immunogenic than MC38 cells and therefore are less likely to elicit an immune 
response (Lechner et al., 2013).  This is why we utilized a B16F10 tumor model for the 
initial in vivo studies because the expected differences between untreated and treated 
B16F10 tumors would be much more noticeable than for MC38 tumors.  In additional 
studies with a MC38 tumor model the differences in recruited immune cell populations 
may potentially be more pronounced as the overall immunogenicity of the tumor will be 
greater.   
 Furthermore, the methodology by which we isolated and analyzed the TIL 
population may need to be optimized.  Dissecting and separating the tumor from the rest 
of the surrounding tissue can be a difficult process and lead to variability in the amount of 
the tumor that is successfully recovered.  This may contribute to the low amount of 
isolated TILs in our experiments.  A Percoll density gradient media was utilized to 
separate the TILs from the rest of the cells but an alternative density gradient media may 
yield a higher recovery percentage.  Also, in our experiments we evaluated the amount of 
TILs with surface marker staining and flow cytometry analysis.  However, in the 
previous study in which higher intratumoral CXCL13 correlated with increased TILs, the 
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immune cell tumor population was assessed via transcriptional profiling (Bindea et al., 
2013).  This type of analysis may yield more precise results and higher levels detection of 
TILs and should pursued be in future studies.   
 Another challenge for this type of analysis is that a static readout may not best 
capture immune cell tumor recruitment via CXCL13 administration.  For this study, the 
tumors were analyzed 24 hours after CXCL13 injection.  However, the exact time it takes 
for B cells and T cells to migrate to the tumor site has not been strictly defined.  A more 
dynamic animal model which enabled real-time in vivo lymphocyte tracking would help 
us better understand how CXCL13 impacts lymphocyte migration into the tumor space.  
For instance, magnetic resonance imaging has been utilized to track labeled T cells to 
tumor sites (Liu & Li, 2014).   This is a developing area of research with challenges 
associated with cell labeling, impact on cell function, and attaining accurate signal.  
However, this type of approach would help elucidate how CXCL13 is able to alter the 
immune cell tumor population and define the mechanisms by which it can delay tumor 
growth.  
 Although these in vivo experiments with free CXCL13 are informative for 
understanding the potential effect of CXCL13-loaded TSLs on tumor growth, there are 
some expected differences.  The free CXCL13 that is injected is most likely immediately 
cleared and degraded from the tumor site within minutes of injections.  The CXCL13-
loaded TSLs have demonstrated the ability to both release gradually at physiological 
temperature and rapidly upon exposure to mild hyperthermic temperatures.  Also, the 
CXCL13-loaded TSLs have shown to improve the plasma half-life of CXCL13.  
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Therefore, we hypothesize that CXCL13-loaded TSLs that accumulate near the tumor site 
would have improved sustained chemokine release and recruitment of immune cells over 
time compared to free CXCL13.  At the same, heating at the tumor site can induce a 
bolus release of CXCL13 and has been shown to improve the permeability of the tumor 
vasculature which many potentially facilitate greater CXCL13 tumor accumulation and 
immune cell tumor recruitment.  This has been demonstrated in human xenograft mouse 
models when Doxorubicin-loaded LTSLs administered in combination with mild 
hyperthermic heating at the tumor site resulted in increased tumor accumulation of 
Doxorubicin compared to Doxorubicin-loaded LTSLs without heating (Needham et al., 
2000).  Additionally, several tumor types have been shown to be susceptible to heating so 
coupling the CXCL13-loaded TSLs with mild hyperthermia near the tumor site may 
prove to be more effective than either alone (Glazer et al., 2011).   
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Chapter 6 Conclusion 
6.1 Summary 
 The work in this thesis highlights the potential of employing nanotechnology for 
cancer immunotherapy.  Furthermore, this thesis details the design process for creating an 
innovative cancer immunotherapy strategy as well as its associated technological 
challenges.  More specifically, the goal of this work was to develop chemokine-loaded 
TSLs to facilitate chemokine delivery in an effort to promote immune cell recruitment, a 
critical process for an effective antitumor immune response.  The results of this work 
demonstrate that chemokines can be loaded and released using TSLs.  In this thesis, 
chemokine-loaded TSLs were shown in vitro to promote immune cell recruitment and 
thereby have a therapeutic impact on limiting cancer cell growth.  The scope of this thesis 
was to determine in vitro whether chemokine-loaded TSLs could be potentially leveraged 
in an attempt to bolster the antitumor immune response and limit cancer growth. 
 Chapter 2 aimed to detail the design process for the chemokine-loaded TSLs.  The 
first challenge for this project was determining the most appropriate chemokine for 
recruiting an immune cell population which would most likely positively contribute to 
antitumor immunity.  After evaluating several chemokines, CXCL13 was chosen based 
on its ability to recruit B cells and previous studies in which it demonstrated a positive 
correlation with cancer patient survival.  Another challenge was determining the most 
efficient liposome formulation process for encapsulating the chemokine inside TSLs.  
Chemokines are orders of magnitude larger than what is typically encapsulated into 
liposomes so we had to consider various loading techniques.  With this in mind, we 
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utilized and adapted the REV process, a method that has been successfully used to 
encapsulate large oligonucleotides, to encapsulate chemokines within TSLs.   
 Chapter 3 aimed to optimize the chemokine-loaded TSLs’ stability in an in vivo 
like environment and ability to rapidly release upon exposure to mild hyperthermic 
temperatures.  Nanoparticles are commonly evaluated in an ideal environment such as a 
PBS solution and under characterized in a biological system (Strojan et al., 2017).  
Therefore, the chemokine-loaded TSLs were tested and modified in cell culture and in 
vivo like environments early in development before biological experiments were 
performed.  A number of modifications were made to the original LTSL composition to 
develop TSLs with improved stability at physiological temperature.  The modified TSLs 
also exhibited improved temperature-sensitivity.  Additional experiments demonstrated 
that the TSLs were capable of releasing gradually over time at physiological temperature. 
 Chapter 4 sought to evaluate the efficacy of the CXCL13-loaded TSLs in 
recruiting immune cells and limiting cancer cell growth.  The aim of Chapter 4 was to 
determine whether the CXCL13-loaded TSLs would be able to operate as a potential 
cancer immunotherapy.  Although in Chapter 3 we had established that the CXCL13-
loaded TSLs were able to release CXCL13, it was undetermined whether this released 
CXCL13 was still functional and able to promote immune cell migration.  There are 
multiple steps in the liposome formulation process and proteins can degrade over time so 
this was not a trivial matter to consider.  The CXCL13-loaded TSLs were successfully 
able to promote immune cell recruitment.  Next, an in vitro evaluation of the impact of 
the CXCL13-loaded TSLs on cancer cells was performed to mimic their expected effect 
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in vivo of increased immune cell tumor recruitment equating to greater tumor inhibition 
by the immune system.  By the increasing immune cell recruitment, the CXCL13-loaded 
TSLs were able to limit cancer cell growth.  These functional experiments demonstrate 
the potential of utilizing CXCL13-loaded TSLs to enhance immune cell recruitment and 
combat tumor growth.  
 Chapter 5 evaluated the administration of free CXCL13 in vivo so that we may 
postulate on the effect of CXCL13-loaded TSLs in future in vivo studies.  There has been 
limited previous information on CXCL13’s therapeutic impact on cancer as well as its 
plasma half-life.  In general, chemokines and cytokine-based therapies are uncommon 
and hindered by their short plasma half-life.  This was exemplified in Chapter 5 when 
CXCL13’s plasma half-life was assessed and determined to be quite short and 
comparable to other similar biomolecules.  Additionally, injected CXCL13 was shown to 
promote a delay in tumor growth.  These results as well as previous studies suggest that 
CXCL13 may be employed to improve immune cell tumor recruitment in an effort to 
combat tumor growth.  Both of these in vivo experiments provide the framework for 
future in vivo CXCL13-loaded TSLs studies in which they are employed as a cancer 
immunotherapy.  
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6.2 Future Directions 
6.2.1 Preclinical animal studies 
 The results presented in this thesis detail the processes involved with designing 
and developing an innovative cancer immunotherapy strategy.  In addition, preliminary in 
vivo studies were performed to evaluate the feasibility of translating CXCL13-loaded 
TSLs to animal models and patients one day.  The results with free CXCL13 suggest that 
CXCL13 encapsulated within TSLs may be effective for delaying tumor growth.  
However, a number of challenges still remain such as the determining the optimal dosing 
regimen for patients. In the in vivo cancer mouse studies, an initial dose of CXCL13 was 
given with the cancer cells then subsequent doses were administered shortly after tumor 
establishment.  This initial dose of CXCL13 cannot be administered to patients as they 
will receive treatment after the tumor has already been established.  Therefore, the 
quantity of CXCL13 required to have a therapeutic impact will likely need to be higher 
than in our preliminary studies.     
 Additionally, the effective dose of CXCL13 that is intravenously administered as 
free CXCL13 or encapsulated inside TSLs is not the same, as the amount that localizes to 
the tumor site will be quite different.  As shown in Figure 5.1, the plasma half-life of free 
CXCL13 is extremely rapid.  Based upon previous work with PEGylated liposomes, we 
expect that encapsulated CXCL13 will have increased plasma half-life which will likely 
to lead to greater accumulation of CXCL13 to the tumor site compared to free CXCL13.  
Therefore, the CXCL13-loaded TSLs will have a greater effective dose at the same initial 
administered dose than free CXCL13.  Additionally, the temperature-sensitivity aspect of 
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the TSLs, can be leveraged with HIFU to trigger a bolus release of CXCL13 at the tumor 
site.  Also, the CXCL13-loaded TSLs can be allowed to accumulate at the tumor site and 
gradually release over time to ensure sustained immune cell recruitment over.  In our 
preliminary in vivo studies, free CXCL13 was administered every 2-3 days but the 
CXCL13-loaded TSLs may not need to be administered as frequently as they gradually 
release over time and may prove to be just as effective as repeated injections of free 
CXCL13.  Ultimately, multiple studies must be performed to determine which is the 
optimal release strategy, gradual or rapidly with heating, and dosing regimen for various 
tumor types.   
 
6.2.2 Improving Efficacy 
 Furthermore, CXCL13-loaded TSLs will be most effective as cancer 
immunotherapy by employing them in combination with existing conventional 
chemotherapeutics or immunomodulatory agents.  As a standalone treatment, the 
CXCL13-loaded TSLs will likely be effective in improving immune cell tumor 
recruitment but that alone may not lead to complete removal or destruction of the tumor.  
In the preliminary in vivo studies, CXCL13 was effective in delaying tumor growth but 
after treatment ceased all the mice began to exhibit tumor growth.  This suggest that 
CXCL13 is helpful in enhancing the antitumor immune response, but alone is not 
effective in completely preventing tumor growth and requires an additional therapy to be 
effective. 
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 Furthermore, administering a cancer chemotherapy prior to CXCL13-loaded 
TSLs may potentially have a synergistic effect.  As stated in Chapter 5, conventional 
chemotherapies promote cancers cell death making them more readily available to be 
phagocytosed by APCs and have correlated with increased TILs (Galluzzi et al., 2015).  
With the addition of CXCL13 at the tumor site, a greater amount of immune cells will be 
recruited to the damaged tumor leading to increased phagocytosis and recognition of the 
cancer cells.  The initial chemotherapy essentially sensitives the tumor cells to be 
identified and phagocytosed by the recruited immune cells leading to a more effective 
antitumor immune response.  This combinatorial strategy will enhance immune cell 
tumor recognition and immune cell tumor localization, two processes necessary for an 
effective antitumor immune response.  Furthermore, the combination of cisplatin and 
CXCL10 is a successful example for this approach (Li et al., 2005).  The challenge with 
this strategy is determining the optimal time span between administering the initial cancer 
chemotherapy and the CXCL13-loaded TSLs.  On one hand, if the time span is too short 
then the recruited immune cells will be exposed to the cancer chemotherapy and be 
harmed.  On the other hand, if the time span is too long then the tumor cells will not be as 
sensitized and primed for phagocytosis by APCs.  Determining the optimal therapeutic 
window will lead to an efficacious cancer treatment.  However, this approach may be 
ineffective for the treatment of tumors with highly immunosuppressive 
microenvironment in which case further immunomodulation would be required.   
 With this in mind, CXCL13-loaded TSLs can be combined with an established 
immune checkpoint inhibitor such as Ipilimumab, a CTLA-4 inhibitor that has shown 
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success in treating advance metastatic melanoma (Lipson et al., 2011).  Ipilimumab 
works to block CTLA-4, an inhibitory receptor on cytotoxic T cells, thereby allowing 
these cells to recognize and attack cancer cells.  The CXCL13-loaded TSLs will enhance 
the ability of B cells to stimulate and act as APCs for T cells at the tumor site, leading to 
a more robust T cell-mediated antitumor response.  Both of these therapies positively 
impact T cell antitumor activity so they may have additive or synergistic effects.  It is 
also possible to load TSLs with a variety of chemokines so that T cells and additional 
APCs are recruited.  These chemokine-loaded TSLs could be used in combination with 
an adoptive cell transfer approach such as CAR T cells to increase the amount of 
engineered cells that are recruited to the tumor.  This approach would be most beneficial 
for the treatment of solid tumors, which have shown to be challenging to treat with CAR 
T cells (D’Aloia et al., 2018).   
 Additionally, tumor-associated antigens could be encapsulated in combination 
with CXCL13 to enable recruited immune cells to immediately recognize the tumor and 
initiate a response.  This strategy would greatly improve immune cell tumor recognition 
and enable a more rapid response as APCs would be directly fed tumor-associated 
antigens and be able to more quickly present antigens to T cells.  However, one drawback 
of this strategy is that it requires knowledge of the tumor and its associated antigens 
which can challenging for different tumor types (Kawakami et al., 2004). 
 Furthermore, CXCL13-loaded TSLs could be combined with an 
immunostimulatory agents to promote immune cell activation.  There are a number of 
soluble factors that initiate immune cell activation, such as B cell activating factor 
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(BAFF), that can in future studies be jointly encapsulated with CXCL13 into TSLs.  
BAFF is a cytokine that stimulates B cell activation and has been shown to co-stimulate 
T cells (Huard et al., 2001).  This cytokine has a similar structure and size as CXCL13 so 
it should be able to be encapsulated into TSLs using similar methods as outlined in this 
manuscript.  A combination BAFF and CXCL13-loaded TSLs would be able to both 
recruit and activate immune cells to fight tumor growth.  Careful studies must be 
performed to ensure that this strategy does not induce negative side effects such as 
inflammation and autoimmune responses.    
 As cancer treatments are becoming increasingly combinatorial, it serves that the 
best approach for the CXCL13-loaded TSLs to be utilized as an effective cancer 
treatment would be to work in combination with one, if not multiple, of these approaches.  
An approach which systematically aims to improve immune cell tumor recruitment, 
immune cell tumor recognition, and immune cell activation will be effective for treating 
most if not all types of cancer.  The optimal combination would feature CXCL13, tumor-
associated antigens, and an immunostimulatory molecule encapsulated in TSLs which 
would facilitate all the necessary steps needed to initiate and sustain a robust antitumor 
immune response.  Although this project only focuses on one aspect, immune cell tumor 
recruitment, of antitumor immunity, it is a necessary step towards developing more 
comprehensive cancer immunotherapies of the future.  
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